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Overview 
 
This thesis explores the topic of Alzheimer’s disease (AD) and the earlier 
clinical state of mild cognitive impairment (MCI), with a particular focus on early 
identification and therapeutic intervention. The first part comprises a systematic 
review of the literature base examining the efficacy of transcranial direct current 
stimulation (tDCS; a form of non-invasive brain stimulation) in the treatment of MCI 
and AD. Specifically, this review focuses on the efficacy of tDCS for improving 
cognitive outcomes in MCI and AD patient groups. A database search identified 
fourteen studies that examined the relationship between tDCS and cognitive outcomes 
in these patient populations. The findings of these studies were summarised separately 
for MCI and AD patient groups. Results in both patient groups were found to be 
tentatively positive, however minimal research was carried out with MCI patient 
groups. Further, the heterogeneity of the identified research designs limited firm 
conclusions as to the factors associated with efficacy.  Results are considered in 
tandem with an assessment of methodological quality. Consideration is given to the 
clinical implications of these findings, as well the areas that would benefit from further 
exploration in future research. 
In the second part of this thesis, an empirical paper is presented that examines 
the utility of a novel spatial memory task in the identification of early AD 
symptomatology. A virtual reality (VR) object-location memory task (OLT) was used 
to assess aspects of spatial memory that are underpinned by brain regions known to 
be affected in the earliest stages of AD: the hippocampus and entorhinal cortex (EC). 
In order to assess the utility of this task in a proof-of-concept study, the OLT was 
administered to patients diagnosed with amnestic MCI (aMCI), a diagnosis that 
represents a high-risk for conversion to AD, and healthy control participants. 
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Alongside the OLT, a comparator battery of neuropsychological tests and a flat-screen 
measure of hippocampal function were administered as an index of the construct 
validity of the task. Results showed that there were significant group differences in 
performance on the OLT, and that task performance was able to predict group 
membership (aMCI or control) with a high degree of accuracy. Further, OLT 
performance was shown to be correlated with comparator measures of cognitive 
function. These results were interpreted as evidence for the utility of the OLT as a 
diagnostic measure. The implications of these findings were discussed in terms of the 
brain regions that the OLT may recruit, as well as the limitations of this study and how 
these might be addressed in future research. 
The third and final part of this thesis is a critical appraisal of the research 
process. This offers a reflective exploration of the experiential components of the OLT 
and how these might compare to more traditional measures of neuropsychological 
assessment. The emotional challenges associated with neuropsychological assessment 
are discussed, making use of quotes from the author and prominent AD spokesperson, 
Terry Pratchett. This section also includes reflections from the researcher on the 
process of carrying out this research, and the learning that took place as a result.  
This is a joint thesis, carried out with Adrienne Li (DClinPsy, 2018); a 
summary of the contributions of each author to this study is given in Appendix E. 
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Impact statement 
 
The current study has a number of implications both in the domains of 
academic research, as well as clinical utility. In academic terms, this project represents 
a forward step in the use of commercially available virtual reality (VR) technologies 
in integrative neuroscience and clinical research. Here, we have demonstrated the 
successful use of novel, fully-immersive VR with a healthy older adult population, as 
well as with individuals who experience clinically significant cognitive difficulties. 
This is something that is not currently routinely practiced within academic research 
and therefore represents an important contribution to the methodological research 
base.  
More specifically, the current study shows that VR paradigms can be used to 
assess aspects of neurological functioning that may not be routinely assessed in either 
pen-and-paper neuropsychological tests, nor in flat-screen computer tasks. Immersive 
VR paradigms, such as that employed in the current study, are uniquely placed to 
assess aspects of spatial learning that incorporate movement-related feedback – such 
as spatial learning that is supported by the entorhinal cortex (EC). Here, we have 
provided preliminary evidence that a VR paradigm targeting these aspects of spatial 
memory can be used to distinguish cognitively impaired patients from non-impaired 
counterparts. Future research may then build on this by demonstrating a link between 
performance on such measures and neuroimaging data, as well as through establishing 
a link between task performance and conversion to Alzheimer’s disease (AD) over 
time. Both of these research aims would further support the concept that VR measures 
of spatial memory may be used to assess EC functioning that may be compromised in 
at-risk groups. 
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This research also has a number of potential clinical benefits. This work 
supports previous research that has demonstrated the utility of spatial learning 
paradigms targeting the hippocampus and entorhinal cortex as an effective tool for 
clinically diagnostic information. Here, we have demonstrated that such a paradigm 
can be used to distinguish individuals with cognitive impairment from non-impaired 
counterparts. It is yet to be shown that this tool can be used to distinguish AD 
pathology from other forms of cognitive impairment, however it does lay the 
groundwork for future studies that may do so. If it can be shown that tests such as 
these are able to distinguish underlying AD pathology from non-AD cognitive 
impairment, then this would lend strong support to the use of spatially-informed VR 
tasks in the early diagnosis of AD.  
A significant implication of the current study is that it speaks to the potential 
integration of ecologically valid technology into clinical practice. To date, the high 
expense of VR software has rendered this an impractical means of neuropsychological 
assessment either in research or clinical practice. However, the high-quality and 
readily available commercial VR software opens up potential new avenues for the use 
of VR in clinical assessments. This is particularly the case when considered in relation 
to the high cost of neuropsychological assessment, which in some cases are in fact 
more expensive than some commercial VR equipment, while offering reduced 
ecological validity and, potentially, less specific focus on symptoms relevant to the 
early stages of AD. 
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Part 1: Literature Review 
Transcranial direct current stimulation (tDCS) as a therapeutic 
tool in Alzheimer’s disease and Mild Cognitive Impairment. 
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Abstract 
Aim: There is a clinical need for the identification of efficacious therapeutic tools 
for the treatment of mild cognitive impairment (MCI) and Alzheimer’s disease (AD). 
This review aimed to assess the use of transcranial direct current stimulation (tDCS) 
as a treatment for MCI and AD, with a focus on cognitive outcomes. 
Method: A systematic review of the literature was carried out using the 
databases PsychINFO, PubMed, MEDLINE and EMBASE. Data were synthesised in 
a narrative format and included consideration of methodological quality, assessed 
using the QualSyst tool. A manual search of citations and references was performed 
in adjunct. This process identified 1652 papers that were screened for eligibility. 
Results: Fourteen papers met eligibility criteria for inclusion in the current 
review. Of these, three addressed the use of tDCS in MCI patients, all of which 
reported positive clinical outcomes on measures of cognition. A further eleven papers 
addressed the use of tDCS for AD patients. Findings in this regard were again largely 
positive, with eight studies reporting improved clinical outcomes following the use of 
tDCS. Three high quality studies reported negative findings, making firm conclusions 
difficult to draw.  
Conclusions: The literature is tentatively in support of the therapeutic use of tDCS 
for cognitive outcomes in MCI and AD. It was difficult to draw firm conclusions 
regarding efficacy, or the specific factors that may contribute to beneficial therapeutic 
outcomes, largely due to the heterogeneity in study protocols.   
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1 Introduction 
Alzheimer’s disease (AD) is a neurodegenerative disorder characterised by 
progressive deterioration in memory and cognitive functioning, with particular early 
deficits noted in episodic memory, alongside behavioural disturbances (e.g. e.g. 
McKhann et al., 1984). It is widely recognised that AD represents a rapidly increasing 
public health burden, with sources estimating that 1 million people in the UK will have 
been diagnosed by 2021 (Alzheimer’s Society, 2014). Consequently, the identification 
of efficacious treatments for AD has become a high research and public health priority 
(e.g. WHO, 2012). Despite this increased focus, current therapeutic efforts have been 
recognised as having limited value in altering disease progression.  
It is recognised that the cognitive deficits linked to AD exist on a continuum 
and likely begin at an earlier stage, clinically referred to as mild cognitive impairment 
(MCI). MCI is diagnosed when an individual presents with marked cognitive decline 
in one or more domains in the absence of a functional decline in daily activities (Albert 
et al., 2011). While it is understood that MCI is a broad diagnostic category, associated 
with varied aetiology, symptomatology and clinical outcomes, there remains a 
subsection of individuals for whom it represents a prodromal stage of AD; this is 
primarily thought to be those presenting with an amnestic variant of the condition 
(aMCI; e.g. Fischer et al., 2007). For this reason MCI and AD are increasingly viewed 
as two points on a continuum of impairment, associated with varying degrees of 
neuropathology and cognitive difficulty, but nevertheless underpinned, in many cases, 
by a shared pathology. 
To date, the therapeutic focus for AD has centred on pharmacological 
interventions. This approach is based on the principle that a neurotoxic build-up of 
proteins are responsible for cognitive decline through the degeneration of cortical 
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tissue (e.g. Ramirez-Burmudez, 2012). Intercellular plaques made up of b-amyloid 
aggregates are thought to contribute to neuronal inflammatory processes and, it is 
argued, to the development of intracellular neurofibrillary tangles made up of 
hyperphosphorylated tau (Mattson et al., 1992). These neurofibrillary tangles are also 
thought to contribute to neuronal death due to the damage they inflict on the 
cytoskeleton. Based on this understanding, a number of drugs have been developed 
that seek to prevent the further spread of the neuropathological processes that underpin 
AD. These fall into two broad classes of drugs: acetylcholinesterase inhibitors and 
NMDA-receptor antagonists (Bishara, Sauer & Taylor, 2015). The former seeks to 
promote cholinergic transmission, which is otherwise compromised due to the loss of 
cholinergic neurones and reduced levels of acetylcholine, while the latter aims to 
reduce neuronal loss caused by excitotoxicity (i.e. neuronal death due to over-
exposure to glutamate, an excitatory neurotransmitter). However, despite the 
promising theoretical backdrop to pharmacological intervention, in practice the 
literature has struggled to provide strong or consistent support for the efficacy of these 
drugs, with some studies reporting a success rate of as little as 0.4% (Cummings, 
Morstorf & Zhong, 2014). Where positive clinical gains are reported, these are often 
associated with small effect sizes and, as is the case with all pharmacological 
interventions, side-effects. While cognitive interventions, such as cognitive 
stimulation therapy, have offered some positive outcomes for AD patients (Spector et 
al., 2010), these are aimed primarily at later stage intervention and clinicians may face 
a number of practical challenges in their implementation (Choi & Twamley, 2013). 
Further, a distinction must be drawn between therapeutic efforts towards symptom 
management as compared to those that seek to effect change via altering the course of 
disease progression; while pharmacological treatments and cognitive therapies may 
15 
 
act toward the former goal, there remains a dearth of therapies aiming to effect change 
at a neuropathological level. 
In this vein, there is growing support for the use of non-invasive brain 
stimulation techniques as an alternative intervention in neurodegenerative disorders 
(e.g. Hansen, 2014). Non-invasive brain stimulation is an umbrella term that may refer 
to multiple specific methods of intervention, primary among which are transcranial 
magnetic stimulation (TMS) and transcranial direct current stimulation (tDCS). 
Transcranial stimulation differs from both pharmacological and cognitive 
interventions in that it allows for change to be affected at a direct neurological level, 
although the precise mechanisms of action depend on the method of stimulation used. 
In the case of TMS, changes in neuronal excitability are induced through the 
generation of a local magnetic current. The duration and intensity of the magnetic 
current, as well as the number of sessions an individual undergoes, are thought to 
regulate the extent of the impact (e.g. Guerra et al., 2011).  
In contrast to TMS, tDCS is thought to induce a mild electrical current that 
may either increase or decrease neuronal excitability, dependent on the polarity of the 
current. Broadly, it is thought that anodal stimulation increases the membrane 
potential by a magnitude of several millivolts, while cathodal stimulation decreases it 
(Nitsche et al., 2008). In this way, tDCS may contribute to either increased or 
decreased neuronal firing in a polarity dependent manner. The mechanisms underlying 
the long-term after effects of this form of stimulation are yet to be fully understood, 
however it has been proposed that they may enhance synaptic plasticity through long-
term potentiation (LTP) or long-term depression (LTD)-like processes. This idea is 
supported by research demonstrating that NMDA receptor agonists are successful in 
enhancing the synaptic effects of tDCS (Nitsche et al., 2004), while NMDA 
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antagonists suppress these effects (Fritsche et al., 2010); given the known role of 
NMDA receptor in LTP-dependent learning, this suggests that tDCS may operate via 
similar mechanisms. This is unlikely to constitute the whole story as many other 
factors, such as increased post-stimulation levels of brain derived neurotrophin factor 
(BDNF), are associated with tDCS (e.g. Fritsch et al., 2010).  However, it does allow 
us to begin to construct a picture wherein tDCS application modulates cortical 
excitability in both the short and long term via complex neuromodulatory processes, 
all of which suggest that it has potential as a tool for the enhancement of learning and 
memory.   
There is emerging evidence that tDCS can be used to successfully enhance 
cognitive outcomes in healthy participants; for example, Martin, Lui, Alonzo, Green 
& Loo (2014) showed that anodal tDCS applied to the dorsolateral prefrontal cortext 
(DLPFC) could be used to improve performance on a working memory cognitive 
training. Researchers compared performance on a dual n-back working memory task 
across conditions of active and sham stimulation and found that those in the active 
treatment condition were more accurate in their responses and showed a steeper 
learning curve; it should, however be noted that these improvements did not translate 
into post-stimulation performance improvements, as no group differences were noted 
during ‘offline’ task performance at follow-up.  The finding of enhanced working 
memory performance associated with anodal tDCS has been supported elsewhere (e.g. 
Talsma, Kroese & Slagter, 2017; Gill, Shah-Basak & Hamilton, 2015). Indeed, other 
researchers have gone further in showing that the effects of tDCS can not only be 
demonstrated during online stimulation, but may also be sustained at follow-up. 
Meinzer et al. (2014) showed that anodal tDCS applied to left temperoparietal areas 
during a language acquisition paradigm enhanced performance in active as compared 
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to sham stimulation. The magnitude of these changes is also notable, with performance 
differences in recall associated with a medium-large effect size (Cohen’s d = 0.73) 
reported at the final learning session and a medium effect retained at follow-up 
(Cohen’s d = 0.6).  
The use of transcranial stimulation as a tool for enhancing cognitive outcomes 
has not been limited to healthy populations, but has increasingly been applied as an 
intervention in the neurodegenerative disorders. As the field of transcranial 
stimulation has developed, a number of reviews have aimed to assess the efficacy of 
these techniques in the treatment of AD or MCI (e.g. Nardone et al., 2012; Gonslavez 
et al., 2017). Most recently, Birba et al. (2017) evaluated the literature on both TMS 
and tDCS in parallel for MCI patients. They concluded that results were mixed, and 
attributed this to the diversity of methodological approaches. Somewhat earlier, a 
similar combination review focussing on AD patients identified evidence of cognitive 
improvement associated with transcranial stimulation, however again noted the mixed 
nature of results and the limited conclusions that could be drawn (Elder & Taylor, 
2014). Throughout these reviews a clear thread emerges in which the outcomes appear 
tentatively positive, however firm conclusions are hampered by the limited research 
base and diversity of methodological approaches. Further, despite these attempts to 
synthesise the literature base on transcranial stimulation, it is consistently noted that 
the broad methodological applications of either TMS or tDCS individually can hamper 
the possibility of drawing clear conclusions regarding efficacy. There is therefore a 
strong argument for a more refined approach that evaluates the individual contribution 
of TMS and tDCS as independent techniques. In keeping with this, a recent review 
and meta-analysis has examined the unique contribution of repetitive TMS (rTMS) to 
cognitive outcomes in AD, including only methodologically rigorous RCTs in the 
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analysis (Cheng et al., 2017). The authors concluded that there was good evidence that 
high-frequency rTMS improved outcomes for individuals with mild to moderate AD.  
Given the clear clinical and research imperative to identify efficacious treatment 
avenues for AD, alongside the current stagnation in the field of pharmacological 
research, this review aims to examine the current state of play as regards the use of 
tDCS in MCI and AD. The cognitive deficits that develop throughout disease 
progression are the key clinical characteristic of these conditions and the focus of this 
review will therefore be on clinical outcomes related to cognition and memory. 
Through examining both the prodromal and clinical stages of the disease it is hoped 
that any stage-dependent effects, such as can be observed in the use of 
pharmacological interventions, may be identified. The current review therefore aims 
to address the following questions:  
 
(1) Is tDCS an effective method of improving cognitive outcomes for individuals with 
MCI?  
(2) Is tDCS an effective method of improving cognitive outcomes for individuals with 
AD? 
 
2 Method 
2.1 Inclusion criteria 
2.1.1 Participants 
Studies were included if patients had received a primary diagnosis of AD or 
MCI, as assessed by scores on a validated screening tool, such as the Mini Mental 
State Examination (MMSE; Folstein et al., 1975) or  Addenbrooke’s Cognitive 
Examination-Revised (ACE-R; Mioshi et al, 2006), or by nationally recognised 
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diagnostic criteria. In the literature a distinction is often drawn between multi-domain 
MCI and amnestic MCI (aMCI), a presentation characterised by primary memory 
impairment; the latter is thought to be at highest risk of progression to a diagnosis of 
AD (e.g. Fischer et al., 2007). While there is an argument for inclusion of studies that 
focus only on the highest risk individuals (i.e. with a diagnosis of aMCI), in practice 
there is at present a limited research base in this area. Inclusion only of these studies 
would limit significantly the conclusions that could be drawn about the efficacy of 
tDCS at earlier stages of disease progression; therefore at this stage a decision was 
made to retain all studies where MCI was a primary diagnosis.   
2.1.2 Cognitive outcomes 
In order to be included in this review, the outcome of interest was required to 
relate to a domain of cognition and memory. Outcomes could refer to either one 
specific cognitive domain (e.g. visual memory), or to a broader assessment of 
cognition (e.g. the ACE-R). While this limits the conclusions that can be made about 
efficacy as regards specific cognitive processes, it does allow for a broader picture of 
efficacy. Given that AD symptomatology, although relating primarily to memory, can 
result in a broad spectrum of impairment, it was felt that wider inclusion would 
represent a more holistic view of the efficacy of tDCS. 
2.1.3 Measures 
Outcome measures included a quantitative measure of cognition.  
2.1.4 Transcranial direct current stimulation 
Studies were eligible for inclusion if the primary intervention was tDCS, 
although were also included if other interventions, such as cognitive training or 
medication, were used in adjunct. No parameters were set for the duration, location or 
intensity of tDCS, as this represents a further refining of literature that may at this 
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stage be premature. However, the inclusion was limited to a standardised tDCS 
protocol; studies including slow-wave oscillation tDCS were excluded on the basis 
that they operate via different hypothesised mechanisms (i.e. facilitation of sleep-
dependent learning only, which may not be directly comparable to other forms of 
tDCS). 
Where tDCS had been used as a tool to evaluate other aspects of cognition or 
neural processes, these studies were excluded; only those for which tDCS was applied 
as a therapeutic intervention were deemed appropriate for inclusion.  
 
2.2 Search strategy 
2.2.1 Electronic search 
An electronic search of the following databases was carried out: PsychINFO, 
MEDLINE, PubMed and EMBASE. The databases were searched using the terms 
“Alzheimer’s disease” OR “AD” OR “dementia” AND (“tDCS” OR “transcranial 
direct current stimulation” OR “TMS” OR “transcranial magnetic stimulation” OR 
“deep brain stimulation” OR “DBS” AND (“treatment” OR “treat*” OR “therap*” OR 
“therapeutics”)). These search terms were designed to be broad and did not reference 
cognitive outcomes, as the potential terminology used would be too wide ranging. 
Search limits were applied to remove all papers that were not written in 
English, as it was not possible to obtain support with translation. Additionally, any 
studies on non-human subjects were excluded via the filter function.  
2.2.2 Data sorting 
An initial search identified 1652 papers from the above search terms. A screen 
of titles and abstracts was then applied by the researcher in order to exclude those 
studies that did not meet inclusion criteria on this basis.  
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From this, 29 studies were assessed as examining an intervention for tDCS on 
cognitive outcomes in AD or MCI. Following an examination of the full text, studies 
were excluded based on the following: not published in a peer reviewed journal (n = 
9); they reporting on a mixed (i.e. including diagnoses other than AD or MCI) patient 
population (n = 4); use of a sleep-based tDCS protocol (n = 1); and describing only a 
prospective study protocol (n = 1). Fourteen studies were therefore eligible for 
inclusion in the following review. 
 
2.3 Quality assessment 
All papers that met the inclusion criteria were subject to a formal assessment 
of quality using the Qualsyst tool for quantitative research papers (Kmet, Lee & Cook, 
2004). This tool evaluates fourteen methodological and reporting factors including, 
but not limited to, the clarity of research aims, methods, sample size and selection, as 
well as the use of blinding and randomisation. In brief, this tool operates a scoring 
system ranging from 0-2, with a higher score indicating a greater quality of design and 
reporting. Where it was felt that a criterion was not applicable to a given study, it is 
possible to rate this as ‘not applicable’. Subsequent to rating each criterion a summary 
score was given, ranging between 0 and 1. If a criterion was deemed non-applicable 
then it was possible to adjust for this while tabulating the final summary score. In this 
way, only the quality of relevant criterion would contribute to the summary score. This 
is important when considering findings that may span a diverse range of research 
methodology; for example, both RCTs and case study designs may provide clinically 
informative information, and yet it would be a challenge to apply all criterion equally 
to both. This allowed for the inclusion and evaluation of a broader range of clinically 
relevant research. In addition, the QualSyst tool has been shown to have an inter-rater 
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reliability ranging between 73-100% in terms of for quantitative research studies 
(Kmet, Lee & Cook, 2004), making it a valid tool for quality assessment. 
This tool was selected on the basis that it had been designed specifically to 
assess clinical outcomes studies and as such was well-suited for the format of studies 
included in this review. Where studies reported multiple research aims (e.g. assessing 
both neuroimaging and cognitive outcomes), quality was assessed based on the criteria 
as they applied to the measurement of cognitive outcomes only, as these were the focus 
of the current review.  
 
2.4 Data synthesis 
The focus of this review was on change pre-and post- intervention. It was 
therefore considered that the outcomes would be helpfully synthesised meta-
analytically; however, heterogeneity in outcome data across studies precluded this 
possibility. Consequently, the data have been presented in a narrative format. The 
results will first summarise the quality of the papers included, before moving on to a 
consideration of the literature as it applies to MCI and AD separately. This is a helpful 
distinction to draw, as studies invariably intervened with only one of these patient 
groups, as well as being in keeping with the rationale that interventions may have 
differential efficacy at different stages of disease progression. 
The analysis of quality assessment will not include an in-depth assessment of 
each paper included; rather, the literature base to date will be summarised according 
to the relative strengths and weaknesses of the field, as well as providing a brief 
summary of those studies that were ranked among the highest or lowest quality in the 
current review. In this way, we aim to inform the understanding of the current state of 
the field more generally, as well as to highlight the studies for which particular 
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attention – whether positive or negative - is warranted. Further consideration of quality 
assessment will be included into a summary of the clinical outcomes. 
 
3 Results 
3.1 Quality assessment (QA) 
Overall, the studies included in the current review ranged in methodological 
quality between 42% and 93%, therefore representing a broad spectrum of study 
quality. Individual scores for each criterion, as well as summary scores for each study, 
can be seen in Table 1. In order to examine this information in closer detail, we will 
begin first with a summary of those studies that occupied both the highest and lowest 
ends of the spectrum in terms of methodological quality, before going on to consider 
the criteria for which consistently high or low scores were obtained across studies.  
The current review identified Andrade et al. (2016), Bystad et al. (2017), Murugaraja 
et al. (2017) and Marceglia et al. (2016) as the lowest scoring studies in the field, all 
of which received a score ranging between 42% and 54%. With the exception of 
Murugaraja et al., this reflects the case-study design of the studies. For this reason, all 
were necessarily rated as not fulfilling the criterion of appropriate sample size, nor did 
they report any attempt blinding for either subject or researcher. In the case of Andrade 
et al., further issues arose due to the confounding factor of cognitive training 
administered alongside tDCS; no attempts to control for the potential impact of this 
on clinical outcome were reported; consequently, it is difficult to disentangle the 
effects of tDCS from those of the cognitive intervention. 
In contrast, the highest scoring study was also from Bystad et al. (2016), who 
received a score of 93% for their double-blind and sham controlled trial. The 
methodological strengths of this research included the combined use of both subject 
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and researcher blinding, comprehensively described randomisation procedures and 
thorough reporting of results. Here, the only criterion for which a ‘partial’ score was 
given related to the reporting of outcomes and an incomplete description of control 
group selection. Sharing a score of 89%, Cottelli et al. (2014), Suemoto et al. (2014) 
and Khedr et al. (2014) were those studies for whom the next highest ratings were 
given. All three reports received a high proportion of ‘full’ ratings, with weaknesses 
again identified primarily limited to the use of an opportunity sample for patient 
selection.   
Across the studies reported, consistent high scores were obtained in terms of 
the use of appropriate and objective outcome measures. There was no instance of a 
study reporting the use of subjective or non-replicable data, despite the variation in 
the nature of clinical outcomes (i.e. use of both neuropsychological batteries and 
individualised measures of cognition). Further, there was a consistent high standard in 
the interpretation of the data. Further strengths included the use of appropriate 
analytical methods across studies, with only Bystad et al., (2017) receiving a partial 
score; this was assigned due to their use of only descriptive data to report on the case 
study. It is, therefore, in the thorough analysis of robust clinical data that the field to 
date finds it strengths. 
Finally, consistent weaknesses were identified in the areas of patient 
recruitment and blinding of investigators, with only three studies receiving ‘full’ 
scores in the latter instance and no studies scoring above a ‘partial’ fulfilment in the 
former. These are both areas that have important implications for the interpretation of 
findings. The lack of thoroughly outlined recruitment procedures means that it is 
difficult to eliminate the possibility of any bias in participant selection at this stage, 
nor are we able to draw firm conclusions about the generalisability of results outside 
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of a given study. The lack of adequately described researcher blinding protocols 
similarly introduces the possibility of bias in the administration process and 
interpretation of outcomes. These areas therefore represent important weaknesses in 
the field to date.
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Table 1: Quality assessment (QA) ratings according to study 
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Defined 
outcomes 
              
Sample size               
Analytic 
methods 
              
Estimates of 
variance 
              
 
Confounding 
 
              
Reporting of 
results 
              
Conclusions 
supported 
              
 
QA total (%) 
50 50 42 93 79 54 79 75 89 86 93 79 64 88 
 
Key:   = Criterion fulfilled in full;    = criterion partially fulfilled;    = criterion not 
fulfilled;  = criterion not applicable. 
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3.2 Studies with MCI samples 
 
The earliest identified study of tDCS in an MCI population was carried out in 
2015 by Meinzer and colleagues (QA 79%), who studied semantic word-retrieval 
following stimulation of the inferior frontal gyrus (IFG). Importantly, this paper 
recruited participants who had been diagnosed with   amnestic MCI only; this allowed 
them to draw more specific conclusions regarding the therapeutic utility of tDCS for 
individuals with this diagnostic subtype. The authors reported that anodal stimulation 
improved the performance of patients on a computerised word-retrieval task, stating 
that post-stimulation performance was comparable with that of control participants. 
This finding is notable as it is based on a single session stimulation protocol, with 
intensity of stimulation relatively lower in both duration and intensity than many other 
studies. Improvements in measures of cognition are therefore linked, in the authors’ 
view, to short-term modulation of membrane potentials; this is contrasted to longer-
lasting changes that are thought to be linked to protein synthesis following multiple 
stimulation sessions. The main difficulty in the interpretation of these results stems 
from incomplete reporting on the processes of randomisation and blinding. Despite 
this issue this study was assessed as being methodologically robust, lending support to 
the conclusions drawn. 
Subsequently, Yun et al. (2016) (QA 79%) investigated the effect of both 
anodal and cathodal tDCS on memory function, as assessed using the Multifactorial 
Memory Questionnaire (MMQ), a self-report measure of subjective memory function 
(Troyer & Rich, 2002). Stimulation was applied to left dorsolateral prefrontal cortex 
(left DLPFC), an area associated with long-term memory. Following three weeks’ 
stimulation, applied thrice weekly, the authors reported significant improvements in 
both the contentment and ability subscales of the MMQ relative to sham conditions; 
29 
 
this difference was not observed for the strategy subscale. Based on these findings, the 
authors conclude that multiple tDCS sessions do produce improvements in transient 
memory performance. It should, however, be considered that these conclusions are 
based on a self-reported measure of ability. While it may be argued that the use of a 
subjective measure of primary outcomes does align with the main presenting problem 
of MCI – i.e. subjective memory complaints – the parallel use of an objective or 
informant report of cognition would lend support to the conclusions drawn. This 
conceptual limitation aside, the work of Yun and colleagues received a high rating of 
methodological quality, indicating that this is a methodologically robust piece of 
research. 
The most recent research was carried out by Murugaraja et al. (2017) (QA 
50%), who attempted to adapt the study of tDCS and cognition to an Indian setting. 
For this reason, cognitive outcomes were assessed via the Picture Memory Impairment 
Test (PMIT), a measure adapted by the authors in order to assess immediate and 
delayed visual recall while accounting for the variability in language and educational 
background of patients. The cortical target was again the left DLPFC, and anodal 
stimulation was applied. It was reported that patients showed improvement in 
immediate and delayed recall as measured by the PMIT, and that this improvement in 
delayed recall was sustained at one month follow-up. This is the only study with MCI 
patients to report follow up data, and it is promising that this shows evidence for 
sustained improvements after the tDCS protocol has finished. It should, however, be 
noted that this study received one of the lowest ratings of quality in this report. There 
were a number of contributory factors to this low score, significantly among which 
was the lack of blinding of either researchers or participants. In the absence of blinding 
it is difficult to draw firm conclusions regarding the true meaning of these results. 
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Further difficulties were noted in the reporting of participant characteristics and 
recruitment procedures. It is unclear how patients were identified for inclusion in the 
study, nor is there any further information regarding the clinical or personal 
characteristics of the participants; for example, there is no reference to any concurrent 
medication use and the authors provide only the mean age of participants. As a 
consequence, it is difficult to paint a clear picture of the patient group involved in this 
study and it would therefore be inappropriate to generalise these findings to anyone 
outside of the included participants. Nevertheless, this study does represent an 
impressive attempt to adapt and evidence a complex intervention within a culturally 
and clinically diverse patient group, and makes an interesting contribution to the 
current report. 
 
3.2.1 Summary of findings: MCI 
There are relatively few studies that have examined the use of tDCS within an 
MCI patient group. Of the three identified studies, all reported positive cognitive 
outcomes. The standard of methodological quality among these was relatively 
high, with two out of three papers scoring above 75% when assessed using the 
QualSyst tool. Cortical targets were the left DLPFC and the IFG, therefore 
conclusions regarding efficacy can only be made as regards stimulation of these 
areas. There was variability in the manner of outcomes measures, with two papers 
making use of a measure developed by the authors themselves (Meinzer et al., 
2015; Murugaraja et al., 2017) and one reporting subjective memory improvement 
(Yun et al. 2016). Only one study (Meinzer et al., 2015) restricted their work to 
the amnestic subtype of MCI (aMCI), which is most closely linked to future onset 
of AD. Overall, there a positive picture is painted for the use of tDCS in an MCI 
population. 
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3.3 Studies with AD samples 
A seminal paper examining the use of tDCS to treat cognitive symptomatology 
in AD was published by Ferruci et al. in 2008 (QA 88%).  In this article, both anodal 
and cathodal stimulation was used to stimulate temperoparietal (TP) areas, citing 
hypoactivity in AD populations as a rationale for selecting this cortical target. 
Outcomes were assessed via a word-recognition test (WRT) that the authors adapted 
from the Alzheimer’s Disease Assessment Scale-Cognitive version (ADAS-Cog). 
Performance across groups was compared both to a sham stimulation condition and on 
a visual attention task; these conditions were included to allow conclusions to be made 
about whether TP stimulation induces task-specific effects on recognition memory, as 
opposed to broader cognitive changes (e.g. increased attention). They reported that 
only anodal stimulation resulted in improved recognition memory; those who received 
cathodal stimulation performed worse on the WRT and performance was unchanged 
in the sham condition. No stimulation-related changes were observed in the visual 
attention task. These results were based on a single stimulation session and suggest 
promising implications for the use of tDCS in AD. The authors conclude that tDCS 
has therapeutic benefit for the cognitive symptoms of AD, although do not rule out the 
possibility that the results may be linked to changes in attentional processes. While the 
authors report both patient and researcher blinding in addition to randomisation, little 
information regarding these processes is provided. This suggests that the findings are 
likely to be robust, however some caution should be held when interpreting the data 
as we are unable to thoroughly assess these aspects of the protocol.  
Several studies in this area have been carried out by Boggio and colleagues, 
who were among the earliest to investigate the use of tDCS in AD. Their first study, 
published in 2009 (Boggio et al., 2009) (QA 64%), applied tDCS to both the left 
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DLPFC and left temporal cortex. The cognitive outcomes under consideration were 
attention, working memory (WM) and visual recognition memory (VRT), assessed 
respectively via the Stroop task, digit span, and a computerised task of recognition 
memory designed by the experimenters. They reported that relative to sham 
stimulation, active anodal tDCS in both areas enhanced VRT performance, however 
had no such impact was observed in relation to WM or attentional processes. From 
this, it was concluded that tDCS has a specific effect on task facilitation for VRM, 
with broader non-specific effects of attention ruled out.  
This research group then went on in 2012 to assess the long-term effects of 
repeated stimulation, using a protocol refined from this initial study. Boggio et al. 
(2012) (QA 79%) extended their protocol to five sessions of anodal tDCS to the 
temporal lobes. Outcomes were again assessed using the VRM paradigm as a primary 
outcome, however the ADAS-Cog, MMSE and Visual Attention Task (VAT) were 
included as secondary measures of cognition. A follow-up period of four weeks was 
included to assess whether cognitive changes were sustained over time. This study 
replicated the initial finding of VRM improvements following anodal tDCS, and 
further showed that these improvements did persist four weeks post- stimulation. In 
this more recent study, the quality of Boggio and colleagues’ work improved in terms 
of methodological quality, placing it among the most robust studies included in this 
review and increases one’s confidence in the findings. However, it should be 
highlighted that some important concerns remain regarding the lack of investigator 
blinding, which do in some ways limit the conclusions drawn. 
Subsequent to these initial findings, Suemoto et al. (2014) (QA 93%) went on 
to study the impact of lDLPFC stimulation on individuals diagnosed with AD. While 
the primary focus of this study was on apathy, ADAS-Cog outcomes were included as
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a secondary measure. Suemoto and colleagues applied a blinding protocol, with 
patients randomly allocated to receive either active anodal or sham stimulation. In 
contrast to earlier studies, no significant effects on cognitive outcomes were reported 
in this instance. The authors consider the negative findings as potentially relating to 
disease-stage factors, particularly that disease progression may have been too 
advanced to observe changes with a limited number of stimulation sessions. In terms 
of quality, Suemoto’s work represents a very high level of methodological rigor. It is 
therefore important to highlight that these negative findings bear significant weight 
when interpreting this body of literature. 
In the same year, Khedr et al. (2014) (QA 86%) conducted a large-scale study 
on the effects of repeated tDCS over a longer-term follow-up period. Following on 
from earlier studies, the stimulation site was LDLPFC, however cognitive outcomes 
were assessed via the MMSE and performance on the WAIS-III. In contrast to other 
protocols, cathodal stimulation was included alongside anodal and sham as an 
intervention method, with patients allocated randomly to each condition. The authors 
reported that both forms of stimulation were associated with improvements on MMSE 
scores that continued at both one and two month follow-up. WAIS scores were 
analysed as performance, full-scale IQ and verbal IQ; the only significant 
improvement was noted for performance IQ, where cathodal stimulation showed 
greater improvements than sham. It was concluded that the WAIS may not be suitable 
for cognitive assessment in patients with dementia, and for this reason no observable 
effects on cognition were observed on this measure. Along with Suemoto and 
colleagues, this study was assessed as a high quality paper. Any concerns in this regard 
were limited to minor issues relating to reporting and unlikely to reflect any serious 
concerns in study design. Therefore, a good deal of confidence can be placed in these 
results. 
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In an alteration from existing research paradigms, Cotelli et al. (2014) (QA 
89%) included a condition of memory training into the traditional stimulation protocol. 
They coupled tDCS, applied over the lDLPFC, with a computerised training 
programme aimed at improving performance on the Face-Name Association memory 
Task (FNAT), which was the primary cognitive outcome in this study. The training 
programme was individualised based on the baseline performance of each patient and 
centred around an errorless learning method. Performance on the FNAT in this group 
was compared to a control group who took part in cognitive training alongside sham 
stimulation. As a further control, a motor (i.e. non-cognitive) training condition was 
included in which patients underwent the active tDCS protocol while also taking part 
in a motor training programme. The authors reported that improvements were 
observed following cognitive training, regardless of stimulation condition; 
improvements did not differ significantly across active stimulation and placebo 
conditions. This was the case both at the end of treatment and at long-term follow-up 
(2 and 4 months post-stimulation). Again, this study was rated at 89% in terms of 
methodological quality and therefore is considered to be among the most robust in this 
literature base. While it could be considered that the efficacy of the cognitive training 
programme was such that any stimulation-related changes were comparably non-
significant (i.e. non-additive), it remains that in this context tDCS did not offer any 
measurable therapeutic gains over and above cognitive training. 
In a further work from the Ferrucci et al. research team, a more recent study 
has examined the link between tDCS and performance on a word recognition test 
(WRT). Marceglia et al. (2016) showed that in a single stimulation session, anodal 
tDCS applied to temperoparietal areas could induce performance improvements on the 
WRT relative to sham stimulation. Again, the authors report a directional effect 
whereby anodal stimulation was associated with improvements in WRT, while 
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cathodal stimulation was associated with worse WRT outcomes, although these 
findings were non-significant in the latter instance. Given the relatively lower intensity 
of stimulation used in this study, in which only a single active session was 
administered and at lower amplitude than many other studies, this is a notable finding. 
One of the methodological difficulties with this study was the lack of blinding of either 
patients or experimenters, as well as the use of a convenience sample; these factors 
introduce the potential for biased results.  
Multiple of the more recent studies in this field have been carried out by Bystad 
et al.’s research team. The earliest of these (Bystad et al., 2016) (QA 93%) was a 
randomised sham-controlled trial with double-blinding applied throughout the 
intervention period; this was among the highest quality studies included in this review. 
In this instance, the primary outcome measure was the California Verbal Learning Test 
(CVLT-II), used as an index of verbal learning. However, this study reported no 
improvement on any subscale of the CVLT-II, or on any secondary outcome measures, 
which included the MMSE and TMT. The authors attribute their null findings to 
several possible factors, including the use of a fixed stimulation protocol, as opposed 
to individualised localisation for cortical targets. Further, it was noted that the patient 
group showed advanced disease progression and low baseline performance rates, 
potentially indicating that the neuroplasticity thought to be induced by tDCS may have 
been lacking.  
3.3.1 Case studies 
More recently, several researchers have reported the effects of tDCS in single 
case studies. The earliest of such reports comes from Penolazzi et al. (2015) (QA 75%), 
who administered both an active and sham protocol to a man in his sixties, thereby 
placing him in the position of a control for himself. Both pre- and post-stimulation the 
patient engaged in ten daily sessions of cognitive training, comprising the WRT, a 
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verbal working memory task (VWMT), a phonemic fluency task (PFT) and a 
continuous performance task (CPT). Stimulation was applied to the lDLPFC in a series 
of ten sessions, in combination with daily cognitive training. A two-month interlude 
was then given before then repeating an identical cycle, however with sham 
stimulation in lieu of active intervention. The authors reported that the VWMT was 
the only aspect of the training battery to show a treatment-related effect. It is important 
to note that in this study although the patient was blind to the condition, researchers 
were not, thereby introducing the possibility of bias. Despite this, and the lack of 
generalisability inherent in a case-report design, Penolazzi et al.’s report remains the 
highest quality case study to be included in this review, with clear attempts made to 
mitigate the impact of common limitations, such as the lack of control or the reporting 
of purely descriptive data. 
A second such case study comes from Andrade and colleagues (2016) (QA 
42%), who similarly administered lDLPFC stimulation alongside cognitive training. 
In this instance, however, the ADAS-Cog was used as a primary measure of cognition. 
The authors reported improvement on several subscales of the ADAS-Cog, most 
notably in the ‘commands’ and ‘spoken language ability’ domains, where post-
stimulation performance was 100% improved relative to baseline. Other notable, 
although less substantial improvements, were observed in the domains of word recall 
and orientation. While a promising result, this should be interpreted with caution in 
light of the lack of control conditions. Further, it is reported that the patient was also 
receiving both medication and cognitive training with a neuropsychologist at the time 
of the intervention. While this is reported, no attempts are made to control for the 
potential therapeutic effects that either would have on cognitive outcomes. For this 
reason, alongside other issues with study design and reporting, this study was assessed 
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as being the lowest quality in the present review. It is therefore important to interpret 
these findings with caution. 
In 2017 the research group of Bysted and colleagues (QA 50%) went on to 
apply a long-term stimulation protocol in a case-study design, with a 
neuropsychological assessment battery carried out at baseline, midpoint and at the end 
of the intervention. The research team trained the patient, a man in his sixties, to self-
administer anodal stimulation to the left temporal lobe on a daily basis for a period of 
eight months; this was by far the longest period of intervention reported in any 
identified study. The repeatable battery for the assessment of neuropsychological 
status (RBANS) was used in order to monitor cognitive functioning throughout the 
intervention. The authors report stabilisation in cognitive functioning over the study 
period, as well as noting improvements in immediate and delayed recall of 39% and 
23% respectively. As this research uses a case-study design, there are inherently 
limitations in generalisability; however, there were additional difficulties with the 
reporting, with limited information provided as to the nature of patient selection and a 
lack of clarity around study design. For these reasons results should be interpreted with 
due caution. 
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4 Discussion 
4.1 Therapeutic efficacy of tDCS 
The application of transcranial stimulation as a therapeutic tool for MCI and 
AD is relatively recent, with research into the efficacy of tDCS beginning a little over 
a decade ago. Since that time a substantive body of research has emerged, with the 
field growing rapidly. The majority of studies reported positive outcomes on a variety 
of cognitive measures, including both clinical diagnostic tools (e.g. the ADAS-Cog, 
MMSE) and more targeted tools developed for research purposes (e.g. adapted word-
retrieval tasks). However, the findings of the current review are not unanimously 
positive in regards to the therapeutic potential of tDCS. It is clear that tDCS is a 
complex neuromodulatory technique, with factors such as the polarity, intensity and 
3.3.1 Summary of findings: AD 
There are mixed results as to the efficacy of tDCS as a therapeutic tool in AD. 
While the majority of studies (8 out of 11) reported improvements in cognition 
following tDCS stimulation, 3 studies reported no effect. Improved outcomes were 
reported both on measures designed to target specific cognitive process (e.g. 
semantic word-retreival), as well as on battery-based measures of cognition (e.g. 
ADAS-Cog). Cortical targets for stimulation included the dorsolateral prefrontal 
cortex, the inferior frontal gyrus, the left temporal lobe and the temperoparietal 
lobe. Efficacy was reported following tDCS in all of these areas. The only studies 
to report a long-term follow-up of outcomes were Boggio et al. (2012), Khedr et 
al. (2014) and Cotelli et al. (2014). All reported stability in performance at follow-
up; i.e. any immediate improvements were sustained over time, or null effects 
(Cotelli) remained the same at follow-up. 
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duration of stimulation to be considered, as well as the cortical target and cognitive 
outcome of interest. With this in mind, the present review aimed firstly to synthesise 
what is known about its efficacy in both AD and its prodromal stage, before 
considering how these factors may play a role in influencing differential outcomes. 
4.1.1 MCI 
There are relatively fewer studies that focus on the prodromal stage of disease 
progression, with only three meeting criteria for the current review. Of those studies 
that are available, methodological quality was high in only two out of the three reports.  
Therefore despite the positive result reported in these studies, it is too soon to draw 
any firm conclusions regarding efficacy for the use of tDCS in an MCI population. 
Caution should be exercised both due to the small number of papers on which the 
conclusions are based, as well as the limitations inherent in the papers reported. The 
studies themselves rely on relatively small sample sizes, with no study exceeding 
eighteen participants. When considered in combination with the use of opportunity 
sampling, which was a limitation in all reported studies, this raises questions about the 
generalisability of findings.  
Further, it is important to closely examine the nature of the cognitive outcomes 
reported.  Two of these studies reported improvement based on an outcome measure 
developed by the researchers themselves (Meinzer et al., 2015; Murugaraja et al., 
2017). While this does not mean that they do not assess a valid cognitive construct, it 
remains that these studies lack an independent assessment of the primary outcome 
measure and findings are not comparable to other studies. This is problematic, as in 
order to develop a coherent narrative within the literature base, it is necessary to ensure 
some way of comparing outcomes across studies. The third study, conducted by Yun 
and colleagues (2014), also made use of a potentially problematic outcome measure in 
that improvement is measured by subjective patient report. As noted above, this may 
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be theoretically aligned with the subjective nature of MCI, however for firm 
conclusions to be drawn it would be important to consider this in conjunction with an 
objective measure of cognition. 
Given that an MCI diagnosis is associated with diverse clinical outcomes (e.g. 
Abner et al., 2017), it is important to note that this is a potential limitation of the 
literature as it stands.  To date, only one study has attempted to refine the patient 
population to the amnestic variant of MCI (Meinzer et al., 2015), which is most likely 
to be associated with progression to AD. While it is promising that the literature in the 
MCI field to date indicates that tDCS is associated with positive outcomes, it is 
important to bear in mind that while the MCI subtype remains undefined conclusions 
in this regard are limited. For example, it is known that patients with MCI due to 
Parkinson’s disease can also benefit from tDCS (e.g. Manetti et al., 2016). 
4.1.2 AD 
When considering the literature for AD, the picture becomes somewhat more 
mixed. Most studies reported positive outcomes, with the evidence base broadly in 
support of the use of tDCS to enhance cognitive outcomes (e.g. Khedr et al., 2014; 
Boggio et al. 2012); however, there were some notable exceptions. Bystad et al. 
(2016), Cotelli et al. (2014) and Suemoto et al. (2014) all reported no effect of tDCS 
on the cognitive outcome of interest. The reasons postulated for these negative findings 
varied, including a speculation that there may be dwindling effects of plasticity in the 
more severe stages of disease progression, highlighting the importance of considering 
disease stage when evaluating cognitive outcomes. A further technical issue, 
highlighted by Bystad and colleagues (2016), is the use of fixed vs. individualised 
stimulation protocols; the latter refers to the use of computational modelling to take 
into account factors such as skull density, allowing individualised placement of 
electrodes. It is true that all those studies reporting negative findings also made use of 
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a fixed protocol, however there were a number of studies that employed this protocol 
and yet reported findings in support of tDCS. For this reason, any of these explanations 
alone are unlikely to fully account for these negative findings.  
It is also important to note that those studies reporting negative findings are 
also among the highest in terms methodological quality. An association between 
methodological rigour and the likelihood of reporting positive results is notable and 
should be given consideration, as it is important not to rule out the possibility that this 
may in part reflect a true negative outcome for the use of tDCS in an AD population. 
It is a well-reported phenomenon that studies reporting positive findings have a higher 
rate of publication (i.e. publication bias) and that this may skew a literature base. While 
it is not possible to conclude that this is the case on the basis of the present review, it 
is important to highlight this difference and to bear this in mind for future studies; it 
also again highlights the research imperative for further high quality studies in the 
field. 
It is also worth noting that the choice of cortical target did not appear to be 
related to the efficacy of tDCS on cognitive outcomes; those studies reporting negative 
findings chose to target the temporal cortex and the dorsolateral prefrontal cortex, both 
areas that were associated with cognitive improvement elsewhere in the literature. This 
does, however, highlight a challenge in synthesising the literature, in that there was a 
notable lack of consistency in the choice of stimulation site across studies. This may 
potentially be appropriate given that there is also a great deal of heterogeneity in the 
cognitive outcome of interest; it is of both theoretical and clinical importance that the 
cortical targets of tDCS are chosen according to their hypothesised link to a targeted 
cognitive outcome. However, the disparity in both outcomes and stimulation sites does 
result in a literature base that makes it hard to conclude with any certainty that tDCS 
can consistently demonstrate therapeutic utility. In order to move forward, it may be 
45 
 
important to consider the identification of key outcomes of interest; from this point, it 
would then be easier to draw specific conclusions regarding tDCS efficacy. This may 
be a target for a future review, when the research base has expanded sufficiently to 
allow the evaluation of separate cognitive processes. 
There are a number of technical considerations that must be made when 
considering the efficacy of tDCS in this population. First among these is the question 
of stimulation parameters; i.e. the amplitude, duration and frequency at which tDCS is 
applied. Within the studies reviewed here each of these parameters have been varied 
in some way, with some studies employing relatively low amplitude stimulation (e.g. 
1mA), or using only single stimulation sessions. While there is not sufficient evidence 
at this stage to state that any one application protocol is superior to another, it is the 
case that neither a lower amplitude nor less frequent stimulation appeared to be 
associated with poorer outcomes in any of the studies reviewed here.  
There does, however, appear to be a consensus emerging in the literature that 
anodal stimulation is used preferentially over cathodal, with only three studies 
attempting to include the latter condition (Ferrucci et al., 2008; Marceglia et al., 2016; 
Khedr et al., 2014). This may have been based on the initial finding by Ferrucci and 
colleagues that cathodal stimulation was associated with poorer performance on 
cognitive outcomes; this is consistent with the hypothesis that anodal stimulation is 
associated with increased neuronal excitability. Hover, it is worth noting that in the 
case of Khedr and colleagues this was not the case, with both anodal and cathodal 
stimulation associated with improved performance on the MMSE. Therefore while it 
can be concluded that the precedent in the literature to date for the use of anodal 
stimulation, the evidence for cathodal stimulation is not conclusively negative. 
A conceptual issue that warrants consideration is how cognition and memory 
are defined in this context. Cotelli and colleagues speculated that more successful 
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outcomes may be observed for isolated cognitive processes, as opposed to outcomes 
related to associative learning (e.g. the Face-Name Association Test). It is true that 
this was the only study to examine associative mechanisms, with the majority of 
studies assessing outcomes via either a single aspect of memory, or a clinical 
neuropsychological measure (e.g. ADAS-Cog, RBANS). In this instance it is likely 
that a more widely distributed neural network would be activated, and that any short-
term neural changes induced in one location may therefore not be sufficient to induce 
network-wide improvement. Further research into associative outcomes is warranted 
before any conclusions can be made in this regard.  
Only a handful of the studies in the current review have included information 
regarding long-term follow-up (Boggio et al., 2012; Khedr et al., 2014; Cotelli et al., 
2014; Murugaraja et al., 2017). This is important because in order to have true clinical 
utility, it would be necessary for the effects of tDCS to outlast the stimulation session 
by some time; if this were not the case, then it would be hard to justify the cost of 
continued intervention. Of those that did report follow-ups, the outcomes have 
appeared to remain stable over time. Interestingly, this is the case both for single 
stimulation sessions as well as repeated stimulation protocols. Therefore, while the 
small number of studies including follow-up information means that it is premature to 
reach firm conclusions, the literature appears tentatively positive in this regard. 
Previous reviews considering the therapeutic benefits of transcranial 
stimulation have similarly highlighted the mixed nature of the literature, particularly 
in relation to factors such as the stimulation parameters, site of stimulation and 
outcomes of interest (Birba et al., 2017). Given the time elapsed since previous reviews 
of the transcranial stimulation literature, as well as the more refined focus on only 
tDCS, it was hoped that a certain degree of clarity may have emerged in this regard. 
This has not been the case and it remains a challenge to the evidence base that there 
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are such a variety of factors that may influence the apparent efficacy of this 
intervention.  
It was notable that throughout the studies no commentary was made in regard 
to effect sizes. Further, due to either incomplete reporting, the use of non-parametric 
data or alternative estimates of variance (e.g. the reporting of standard error as opposed 
to standard deviation), it was not possible to calculate effect sizes for the majority of 
studies reported. This is relevant as it limits the conclusions that can be drawn 
regarding the magnitude of clinical effect that we might expect to observe when 
applied to real-world clinical settings. Further, it limits the extent to which this can be 
incorporated into considerations of sample size when designing future studies; for the 
purposes of the QualSyst tool, adequate sample size can be implied by the finding of 
significant between group differences. While this is a technically accurate assessment 
it remains that the lack of consideration of power or effect size does not stand out as 
an evident finding across studies. As a result, the magnitude of potential clinical 
benefits cannot be assessed at this time. However, were tDCS to be adopted into 
routine clinical practice for AD and MCI it would represent a new class of therapeutic 
intervention, in which the aim is to promote plasticity through non-invasive 
neuromodulation. The implication of this is the potential for clinically significant gains 
in cognitive function following an initial diagnosis of MCI or AD; this would be highly 
clinically significant in the context of a diagnosis for which the aim is currently only 
to maintain cognitive function and prevent further decline.  
 
4.2 Clinical recommendations 
The overarching finding of this review is that tDCS appears to be a safe and 
potentially effective therapeutic tool for the treatment of cognitive symptoms in MCI 
and AD. This should be interpreted with the caveat that several high quality studies 
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report null findings, therefore efficacy cannot at this stage be said to be conclusively 
demonstrated. It is, however, important to note that the safety of tDCS was not 
explicitly assessed within this review and was not routinely examined as part of the 
study design, with studies inconsistently reporting patient feedback on any adverse 
effects. Based on the literature to date it appears that the strongest evidence base is in 
relation to the use of anodal stimulation, with potential stimulation sites largely 
considered to be the left dorsolateral prefrontal cortex, as well as temporal and 
temperoparietal areas. The choice of stimulation site should be selected based on a 
consideration of the targeted cognitive outcome. Following on from this, it should be 
noted that research to date only supports the use of tDCS in relation to isolated 
cognitive processes, as opposed to associative processes that may depend on the 
contribution of multiple cortical systems. In the majority of studies reviewed, tDCS 
was used as an adjunct to pharmacological interventions. There is therefore no 
evidence to support the use of tDCS as a standalone treatment option; it remains to be 
seen whether this tDCS can be used more successfully when applied in conjunction 
with cognitive training. Currently, it is a challenge to make further recommendations 
as to the most successful manner in which to implement this clinically due to the 
heterogeneity of the research base. Before further conclusions regarding clinical utility 
can be drawn, research must first move towards elucidating the factors that contribute 
to successful versus unsuccessful clinical outcomes. 
 
4.3 Research recommendations 
The difficulty in drawing any firm conclusions from the clinical evidence to 
date is likely to be a reflection of the disparate nature of the research base. In order to 
move forward from this challenge, which has also plagued previous attempts to review 
the literature on transcranial stimulation, it is necessary to consider the current 
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strengths and weaknesses of the literature, both in terms of methodological quality and 
conceptual backdrop. From this, it is possible to inform the next steps in constructing 
methodologically sound and clinically informative research studies. 
A consistent methodological weakness identified across studies was the use of 
opportunity sampling; many studies reported either minimal recruitment from a single 
clinic site or, in some instances, no descriptors were given regarding the process of 
participant selection. Further, it was noted that the lowest quality studies in the current 
review were among the most recent. This is an unusual finding and appears to reflect 
an increased movement towards the use of case study designs. If the research base 
wishes to move forward in quality then it would be necessary to include thoughtfully 
designed multi-site studies that aim to include a patient sample representative of the 
MCI/AD population. 
The current review focussed on the effect of tDCS on cognitive outcomes in 
MCI and AD, with outcomes assessed primarily through performance on 
neuropsychological measures. While it was not the focus of the current review, it is of 
note that measures of daily living and functional performance were not assessed in the 
studies included here. In order to more fully demonstrate clinical utility it would be 
necessary to assess whether any observed cognitive improvements successfully 
translated into improvement on functional outcomes; for example, the Alzheimer’s 
Disease Cooperative Study activities of daily living inventory (Galasko et al.,1997) is 
a tool that assesses functional capacity and could helpfully be incorporated alongside 
cognitive outcomes. Future research in this field would benefit from incorporating 
tools to assess functional outcomes and quality of life, alongside cognitive 
improvement. 
The primary conceptual issue that the literature must address is the diversity of 
approaches taken to the use of tDCS in this patient group. There is little cross-study 
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consistency in the cognitive outcomes of interest, nor is there a firm consensus reached 
on the most effective stimulation parameters (i.e. cortical target, number of sessions 
or duration of stimulation). It would be helpful in this regard to be led by clinical need, 
with a hypothesis-driven approach to addressing the core clinical symptomatology of 
AD and MCI (e.g. long-term memory deficits). Further refinement would also be 
beneficial in the MCI literature in particular, where the potential heterogeneity of the 
patient population hampers our ability to form firm conclusions about efficacy of tDCS 
for prodromal AD. Increased focus on an amnestic MCI patient group would address 
this concern. Finally, studies would benefit from a movement toward the use of long-
term follow-ups as a standard practice in this area of research. For a strong case to be 
made for the use of tDCS in future clinical practice, it will be necessary to demonstrate 
the long-term implications of this intervention. 
 
4.4 Limitations 
There were a number of limitations to the current review that may impact on 
interpretation of the results. Firstly, the results included are restricted to those papers 
that were written in the English language. While this has not prevented the inclusion 
of several studies that were conducted in non-English speaking settings (e.g. 
Murugaraja et al., 2017), it may nevertheless represent a Western skew of the evidence 
base. Further, only those papers that were included in a peer-reviewed journal have 
been included. This was set as a criterion for inclusion in order to ensure the quality 
of the papers assessed; a variety of study designs were included in order to attempt to 
present the broadest possible range of clinical evidence, however it is possible that a 
wider evidence base may be lacking due to this omission. Finally, due to limited 
resources it was not possible to have either the literature screen or the quality 
assessment verified by a second assessor. It is therefore possible that there is some bias 
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in the screening and assessment of papers which would be helpfully addressed by the 
inclusion of a second researcher or independent assessor. 
 
4.5 Conclusions 
The literature to date is cautiously in support of the use of tDCS as a therapeutic 
tool in MCI and AD patients. The studies included present largely positive results in 
terms of cognitive outcomes, which do not appear to be linked to the duration or 
intensity of the stimulation protocol. There are some notable exceptions to this, with 
several high-quality studies reporting null findings. For this reason, it remains 
necessary to take a tentative perspective on the clinical use of tDCS. One key difficulty 
in interpreting these findings is the heterogeneity of the literature, with a wide range 
of stimulation protocols and cognitive outcomes assessed. Further research is needed 
to refine those factors that contribute to successful clinical outcomes, as well as 
defining the cognitive difficulties that may be most helpfully addressed by the use of 
tDCS. 
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Spatial memory deficits in mild cognitive impairment: a virtual 
reality study of hippocampal and entorhinal functioning 
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Abstract 
Introduction: Neurophysiological research has identified that the hippocampus and 
entorhinal cortex (EC) are the brain regions affected in the earliest stages of 
Alzheimer’s disease (AD).  These areas play a key role in spatial memory, notably the 
allocentric location of an individual within an environment, as well as the location of 
objects within an environment. Given that a diagnosis of amnestic mild cognitive 
impairment (aMCI) represents a high-risk for conversion to AD, this study used a 
virtual reality (VR) task to establish whether a spatial memory task sensitive to EC 
and hippocampal function could be used as an early diagnostic measure for AD by 
establishing a proof-of-concept in this (aMCI) patient group.  
Method: Twenty individuals diagnosed with aMCI and twenty-two age-matched 
healthy controls completed a VR study of object-location memory – the object-
location task (OLT). This was followed by a desktop computer assessment of object 
recognition memory, as well as object-environment recognition. Alongside this, a 
comparator battery of neuropsychological tests sensitive to early AD was administered 
in order to assess construct validity of the OLT. 
Results: Performance on the VR component of the OLT was poorer in aMCI 
patients compared to healthy controls. A model containing OLT response accuracy, a 
flat-screen measure of hippocampal function and premorbid IQ was highly significant 
and able to predict the patient status of participants (aMCI or healthy control) with 
95.1% accuracy. Performance on object-only, but not object-context recognition was 
poorer in the aMCI group relative to controls. There were significant correlations 
between OLT performance and the neuropsychological testing battery for aMCI 
patients but not control subjects. 
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Conclusion: The OLT is a useful tool in distinguishing aMCI from healthy controls 
and has the potential to form the basis of a sensitive early diagnostic measure for AD. 
Performance on the VR component of the OLT relates to other known 
neuropsychological measures used diagnostically in AD, supporting the construct 
validity of the task. However, the OLT did not relate to a flat-screen measure of 
hippocampal functioning, potentially suggesting greater EC involvement in this task. 
Implications of these findings are considered and suggestions for future research are 
made. 
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1 Introduction 
 Alzheimer’s disease (AD) is the most prevalent presentation of the dementias 
and, due to the effects of an aging population, represents a growing public health 
concern. It is estimated that 1 million people will receive this diagnosis by 2021 
(Alzheimer’s Society, 2014) and that the number of people diagnosed will double 
every twenty years (Prince et al., 2015). It is statistics such as this that have prompted 
a number of global health initiatives to name the identification and treatment of AD as 
a high public health priority (e.g. WHO, 2012). AD represents approximately two 
thirds of dementia diagnoses and is clinically distinguished from other forms of 
dementia due to the early symptomatic hallmarks of episodic memory loss and 
topographic disorientation (e.g. McKhann et al., 1984; Guariglia & Nitrini, 2009). A 
clinical diagnosis requires that individuals present with a gradual onset of symptoms 
that worsen over time and interfere with functioning (McKhann et al., 2011). While 
anterograde memory loss is considered the most prominent feature of AD, it is 
understood that this is often accompanied by impairment in language, executive 
function, visuospatial reasoning and semantic knowledge that, at later stages, 
progresses to global cognitive impairment (Salmon and Bondi, 1999).  
Important links have now been made between the neuropathology of AD and 
its associated cognitive deficits. From a neurological perspective, AD is distinguished 
from other forms of dementia by the distinct neuropathological profile of b-amyloid 
plaques (Ab) and intracellular tangles of the hyper-phosphorylated neurofibrillary 
protein, tau. Together, these plaques and tangles are understood to contribute to neural 
cell death through inflammatory processes and neuronal destruction (DeLaGarza, 
2003). These neuropathological processes do not appear to occur in a uniform manner 
across brain regions, but rather are likely to begin in the medial temporal lobe, an area 
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associated with episodic memory (e.g. Scoville & Milner, 1957; Vargha-Khadem et 
al., 1997; Squire et al., 2004); specifically, these changes are thought to progress from 
a starting point in the entorhinal cortex (EC) to the hippocampus proper (Braak & 
Braak, 1991).  
 The link between the cognitive and behavioural symptomatology of AD and 
the neuropathological changes that underlie them is now more clearly understood, 
however, this has failed to translate into the development of more efficacious drug 
treatments. For many years the primary treatment options available for AD have been 
pharmacological, with anticholinesterase inhibitors and NMDA receptor antagonists 
as the two primary options (Bishara, Sauer & Taylor, 2015). However, not only are 
there debates as to the degree of clinical benefit associated with pharmacological 
interventions, but these interventions seek only to prevent or reduce the rate of further 
cognitive decline, rather than offering any remediation of symptoms already present, 
which reflect neural damage which may be irreversible. Non-pharmacological 
treatment options include cognitive training paradigms, such as cognitive stimulation 
therapy (CST; Spector et al., 2008) or, more recently, there has been tentative support 
for the use of non-invasive transcranial stimulation (i.e. transcranial magnetic or 
transcranial direct current stimulation) (for a recent review, see Birba et al., 2017 or 
Gonslavez et al., 2017). This latter avenue is in its infancy and it remains to be seen 
how and in what ways it may be incorporated into routine clinical practice. Given that 
current clinical interventions offer only support with maintaining cognitive function 
and reducing further decline, there is a clear imperative for the early identification of 
and intervention in AD. 
 It is now recognized that AD is preceded by a prodromal phase of mild 
cognitive impairment (MCI), in which individuals are symptomatic but do not yet meet 
diagnostic criteria for dementia.  MCI is diagnosed when an individual shows 
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impairment in one or more cognitive domains in the presence of spared functional 
abilities (Albert et al., 2011). However, a significant clinical challenge remains in that 
MCI is a heterogenous diagnosis that includes many individuals who do not progress 
to develop AD. For this reason, a diagnosis of MCI alone is not sufficient to determine 
the likely endpoint or time-course of cognitive impairment; rather, efforts are now 
being made to identify those features of early cognitive decline that are likely to 
progress to a full diagnosis of AD. The term amnestic MCI (aMCI) has been coined to 
refer to specific presentations of MCI in which memory loss is the predominant early 
symptom and this patient group is broadly held to be at highest risk of conversion to 
AD; for example, Fischer et al. (2007) showed a 48% conversion rate to AD among 
aMCI patients compared to a 26% conversion rate in non-aMCI patients over a 30 
month period. While this suggests higher conversation rates in this group, this is 
clearly not conclusively predictive of progression to AD. To date traditional 
neuropsychological tests are not able to reliably differentiate MCI due to AD (MCIad) 
from MCI due to other causes. Studies attempting to differentiate MCIad from non-
AD MCI have provided a number of neuropsychological predictors, including (but not 
limited to) the Trail Making Test-B (Ewers et al., 2012); the Digit Symbol Test subtest 
of the Weschler Adult Intelligence Scale-Revised (Tabert et al., 2006); and the 
Orientation and Memory Subtests of the Cambridge Cognitive Examination 
(CAMCOG; Conde-Sala et al., 2012). While these studies indicate that 
neuropsychological measures are informative in the diagnosis of MCIad, there remains 
a lack of consensus as to clear neuropsychological predictors of conversion to AD. 
While recent advances have made it possible to diagnose MCIad through the use of 
amyloid and tau biomarkers that are detectable in cerebrospinal fluid (CSF), these 
methods are both invasive and costly, rendering them impracticable as a routine feature 
of diagnostic testing.  
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 A promising new source of diagnostically informative research has come from 
rodent studies that are elucidating the contribution of the hippocampus and associated 
regions to spatial and episodic memories. The discovery of cells in the rodent cornu 
ammonis subfield (CA1) that fire in a spatially determined manner based on an 
organism’s location within its environment – termed place cells (O’Keefe & 
Dostrovsky, 1971) - has led to the hypothesis that the hippocampus supports the 
encoding of allocentric spatial frameworks (i.e. information that is encoded relative to 
the environment, as opposed to idiothetic frameworks, which are encoded relative to 
the individual). In this way, the hippocampus is thought to form the neural basis of a 
‘cognitive map’ (O’Keefe & Nadel, 1978). In support of this hypothesis, researchers 
have since identified cells in the neighbouring medial entorhinal cortex (MEC) that 
fire in a regular hexagonal pattern spanning an environment, referred to as ‘grid cells’ 
(Hafting et al., 2005). This has been accompanied by the finding of cells in the 
presubiculum that encode an animal’s heading within space, known as ‘head direction 
cells’ (Ranck, 1984; Taube et al. 1995). A proliferation of both animal and human 
studies has continued to elucidate the factors that contribute to the differential 
involvement of these neural areas in spatial learning and memory. One key avenue in 
this research has been the role of landmarks and environmental boundaries in 
supporting the cognitive map. Doeller, King and Burgess (2008) used fMRI to 
demonstrate the selective activation of the hippocampus under conditions of 
environmental boundary-based learning during an object-location memory task. 
Participants navigated within a circular arena that contained a single landmark and 
were required to learn and identify the location of everyday objects relative to either 
the landmark or arena boundaries. The authors report that the hippocampus was 
activated when object-location learning took place relative to the arena boundary, but 
not when learning was relative to the landmark. Here, we see that the hippocampus 
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acts as a neural substrate for the encoding of allocentric spatial information, and that 
this encoding incorporates salient environmental features. On the basis of these 
findings, more recent thinking has put forward that the role of the hippocampus in 
humans is likely to be in binding event representations to their spatial and temporal 
context – the ‘what’, ‘where’ and ‘when’ of memory formations (Burgess, Maguire & 
O’Keefe, 2010).  
 These findings are important as they provide a clear link between the role of 
hippocampus, the neuropathology and the clinical presentation of AD, thereby 
providing a potential framework in which hippocampal pathology can be used to 
inform diagnostically sensitive measures. In keeping with this, research has 
demonstrated that measures of allocentric spatial memory tasks are sensitive to 
hippocampal dysfunction associated with AD.  The Four Mountains Task (Hartley et 
al., 2007) presents images of landscapes (specifically, mountains) from either the same 
or shifted-viewpoint, hypothesising that hippocampal dysfunction should selectively 
impair image recognition under conditions of shifted-viewpoint, which requires 
allocentric representations of spatial relations. This has indeed been found to be the 
case, with research now showing that not only does performance on the Four 
Mountains Task successfully distinguish dementia due to AD from frontotemporal 
dementia (FTD; Bird et al., 2010; Pengas et al., 2010) – a condition associated with 
non-hippocampal neuropathology – but it can also distinguish individuals with MCIad 
from non-AD MCI (determined by CSF biomarkers) with 100% sensitivity and 90% 
specificity (Moodley et al., 2015). It should be noted that these results derive from 
small samples and may not translate to large-scale community studies; in addition, it 
was noted that specificity was reduced in non-UK samples. However, it remains that 
this is strong evidence that measures informed by neurophysiological research can be 
successfully used to design diagnostically informative measures for AD.  
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 While this has proved an informative and promising research avenue, it 
remains that the hippocampus proper is not the first area to become effected by AD 
pathology; rather, this process begins in the EC (Braak & Braak, 1991), an area that 
provides important input into the hippocampus. It follows that a more complete 
understanding of the role of the EC may guide the design of measures that are sensitive 
to an earlier, potentially preclinical stage of AD-related neuropathology. In this vein, 
attempts are now being made to disentangle the relative contributions of different sub-
regions of the EC. It is widely held that grid cell activity in the MEC supports a form 
of idiothetic (i.e. self-referential) navigation referred to as path integration – i.e. 
navigation back to a start point through integration of vestibular, proprioceptive and 
visual information (McNaughton et al., 2006). In line with this idea, there is evidence 
that path integration is impaired both in the context of normal aging (Harris & 
Wolbers, 2012) and, relevantly, in individuals diagnosed with both AD and MCI 
(Mokrisova et al., 2016). Further, there is evidence that the EC grid representation is 
impaired in healthy individuals who carry a high genetic risk for AD, despite the 
absence of any cognitive decline. Kunz et al. (2015) demonstrated that carriers of the 
APOE-e4 gene - a known risk factor for development of AD - showed reduced grid-
cell-like activation during an object-location task, despite equivalent spatial memory 
performance. When considered together these results indicate that there may be early 
changes in the EC that precede both hippocampal impairment and clinically 
distinguishable cognitive decline.   
 In contrast, the lateral entorhinal cortex (LEC) has been viewed as relatively 
insensitive to spatial changes, but rather associated with encoding of objects within an 
environment (e.g. Hargreaves et al., 2005). This has for some time been viewed as 
evidence of a functional distinction between the MEC and LEC, with these areas 
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hypothesised to provide spatial and non-spatial input respectively (Knierim et al., 
2014). However, emerging evidence now suggests that this distinction is not clear, and 
that the role of the MEC and LEC may be far more complex. Recent theories suggest 
that while the MEC alone is responsible for the processing of idiothetic information, 
the contribution of both LEC and MEC is required for alloethetic navigation (Save & 
Sargolini, 2017). Further, it is thought that factors such as the behaviour of the animal 
and the complexity of the environment may modulate the level of MEC and LEC 
involvement. Studies making use of a free exploration paradigm have shown that MEC 
lesions impair an animal’s ability to identify spatial changes (e.g. object relocation) 
within an environment, while LEC lesions impair recognition of changes that are both 
spatial and non-spatial (i.e. object identity; Van Cauter et al., 2013). Deshmukh and 
Knierim (2011) showed that cells in the LEC exhibited spatially dependent firing only 
in the presence of objects. Further, it has been shown that lesions of the LEC impair 
the ability to recognise item-context associations, but not item recognition per se 
(Wilson et al., 2013). Here, we can see an emerging picture that the MEC and LEC 
contribute to constructing conjunctive representations of item, context and location 
that are likely integrated downstream in the hippocampus.  
 Research into the neural underpinnings of spatial memory represents a 
promising avenue in the assessment of AD, with translation from rodent 
neurophysiological studies to use with human subjects greatly facilitated by the advent 
of virtual reality (VR) systems. VR draws on a tradition of computerised testing and 
refers to systems or tasks that enable individuals to retain a sense of physical presence 
in a computerised ‘virtual’ environment. Garcia-Betances et al. (2015) describe the 
differing levels of immersion that can be obtained via a range of technological 
platforms, such as 3D mounted head displays, and note that the recent advances in VR 
technologies offer a potential tool in both the assessment of AD. VR paradigms offer 
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multiple advantages over pen-and-paper measures of neuropsychological function, 
primary among which are the increased ecological validity of immersive and engaging 
technologies; this is particularly the case in patient groups, such as AD patients, for 
whom sustained attention may be an issue. There is evidence to support the concept 
that performance on VR measures is comparable to real-world performance, with 
Cushman, Stein and Duffy (2008) demonstrating that navigational patterns in 
individuals with MCI and early stage AD was closely related across the two 
paradigms. Further, there is a precedent to show that VR technology can be 
successfully used as a screening measure for MCI. Zygouris et al. (2015) showed that 
a VR task in which participants were required to navigate around a virtual supermarket 
was successful in distinguishing MCI patients from age-matched healthy controls with 
a classification accuracy of 87%.  
Despite the increasing use of VR with AD populations, there remains 
arguments around the ecological validity of the medium – in which older adults, with 
limited exposure to immersive gaming technologies, are asked to envision themselves 
‘within’ a desktop scene. Further, it is clear from examination of the role of the EC 
that this incorporates complex non-visual information, such as vestibular and 
proprioceptive feedback, that are not available in flat-screen mediums. These 
limitations are applied primarily to the use of VR utilising lower levels of immersion, 
with minimal integration of multisensory feedback. However, a recent review 
highlights that research to date does not frequently make use of VR technologies with 
a high level of immersion (Garcia-Betances, Waldmeyer, Fico and Cabera-Umpierrez, 
2015). This is likely due to the fact that, until recently, commercial VR was associated 
with high expense and low quality; however, recent advances have seen the 
introduction of widely available and relatively low-cost commercial systems, which 
increases their potential utility within research and, perhaps, clinical practice.  
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Given that the EC is an area affected by the earliest stages of AD 
neuropathology, it follows that individuals with early stage AD are likely to show 
selective deficits in tasks designed to tap specific aspects of spatial memory, relative 
to non-affected individuals. The current research seeks to draw on literature supporting 
the role of the MEC and LEC in the neural encoding of the location of objects, as well 
as the role of the LEC in conjunctive object-context associations, in order to develop 
a measure of spatial memory sensitive to EC pathology. In addition, the current study 
includes parallels with previous flat-screen VR tasks known to recruit the 
hippocampal-dependent skill of locating an object relative to environmental boundary 
cues (Doeller, King & Burgess, 2008).  
This study draws on literature suggesting that an aMCI diagnosis represents a 
high risk for progression to AD in order to establish a proof of concept in an at-risk 
patient group. Here, we use immersive VR technology that allows participants to 
navigate freely within a virtual environment as a platform for a novel measure of 
spatial memory that aims to assess hippocampal and EC function. This offers a number 
of advantages over desktop measures of spatial memory, including increased 
ecological validity and greater task engagement; this is in addition to the incorporation 
of vestibular and proprioceptive feedback that is known to underlie EC encoding. On 
this basis, we established an object-location memory task that required participants to 
recall the location of objects within a virtual environment. Based on the known role of 
the hippocampus in allocentric spatial memory, particularly when reliant on distal 
boundary cues (Doeller, King & Burgess, 2008), and the role of the EC in object-
location representations, this task was intended to recruit both regions affected in early 
stage AD.  In addition, participants were asked to complete desktop assessment of both 
object and object-context recognition memory. A comparator neuropsychological 
testing battery was included, against which performance on the OLT was assessed. 
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Alongside pen-and-paper diagnostic measures, performance on the OLT was 
compared to the Four Mountains Task (4MT; Hartley et al., 2007), as a known measure 
of hippocampal dysfunction that is sensitive to MCI due to underlying AD (Moodley 
et al., 2015).  
 
Research questions 
(1) Is an immersive virtual reality test of object-location memory able to 
distinguish individuals with amnestic MCI (aMCI) from healthy controls? 
(2) Do patients with an aMCI diagnosis show reduced performance relative to 
controls in the recognition of object-context associations, in the context of 
preserved object-only recognition? 
(3) Does performance on a virtual reality task of object-location memory correlate 
with traditional neuropsychological measures of episodic memory? 
 
2 Methods 
2.1 Design  
This study made use of a quasi-experimental between-subjects design in which 
all subjects completed both the immersive VR and neuropsychological battery. The 
between groups factor was patient status (‘MCI’ or ‘HC’) and within groups measures 
were the performance indices on the VR task, each pen-and-paper test within the 
neuropsychological battery and the Four Mountains (4MT) test (Hartley et al., 2007). 
 
2.2 Participants  
MCI patients were recruited from a hospital-based memory clinic attached to 
the research centre. All participants within the patient group were diagnosed by a 
neurologist with amnestic MCI (aMCI) according to the Peterson criteria (Petersen, 
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2004), which requires that individuals present with: (1) informant corroborated 
memory complaints; (2) objective memory impairment relative to others of the same 
age; (3) preserved general cognitive function; (4) intact functional activities; and (5) 
the absence of dementia.  Participants received an initial memory screening 
comprising the Addenbrookes Cognitive Examination-Revised (ACE-R; Mioshi et al., 
2006) and a Mini Mental State Examination (MMSE; Folstein, Folstein & McHugh, 
1975) in order to determine objective memory disturbance. During their attendance at 
the memory clinic, the attending neurologist discussed the research with patients. 
Those individuals who were interested in taking part in ongoing research then 
completed a consent form allowing members of the research team to contact them in 
the future.  
Age-matched healthy controls were recruited via the Join Dementia Research 
initiative developed by the National Institute for Health Research (NIHR) or were 
spouses of patients.  The MMSE and ACE-R were also administered to control 
participants within six months of their participation in the study. 
Recruitment for both patients and control groups was carried out by research 
staff, including a Research Nurse and doctoral student. Interested individuals were 
contacted via telephone, at which time the study was explained to them verbally and 
an information sheet was also sent out via post (see Appendix B). Participants were 
given opportunities to raise any questions or concerns about the research at this stage, 
as well as prior to their participation in the study. Inclusion criteria across both patient 
and control groups were as follows: (1) Capacity to consent to participation; (2) fluent 
English-speakers; (3) no psychiatric, neurological or substance misuse difficulties or 
learning disability that would interfere with capacity to participate in the 
neuropsychological or VR testing; (4) no sensory or motor difficulties that would 
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interfere with capacity to participate in neuropsychological or VR testing. All 
participants could claim reimbursement for travel expenses. 
 
2.3 CSF biomarkers 
As part of the diagnostic procedure, a subsection of the patient sample also 
underwent lumbar punctures to ascertain the presence of b-amyloid or tau biomarkers 
in the cerebrospinal fluid (CSF). Where this procedure was undertaken, the outcome 
was made available for inclusion in the current study. A positive CSF biomarker status 
indicates the presence of Ab and tau biomarkers, suggesting that cognitive impairment 
is due to underlying AD pathology. CSF status was determined according to criteria 
outlined elsewhere (Shaw et al., 2009), and procedures were carried out by a qualified 
nurse using ELISA assay kits (Innotest, Innogenetics, Ghent, Belgium).  
 
2.4 Ethical considerations 
Ethical approval for this research was given by the Cambridge South NHS 
Research Ethics Committee (REC reference 16/EE/0215; see Appendix B for 
confirmation letter) and was carried out in line with the Declaration of Helsinki 
(WMA, 2013). UCL researchers were granted Visiting Researcher status in April 2017 
(see Appendix C for letter granting Visiting Researcher status). 
 
2.5 Equipment 
The immersive VR component of the object-location task (OLT) was carried 
out on a commercially available VR system, the HTC Vive. The HTC Vive hardware 
comprised a headset with resolution 1080 x 1200 pixels per eye, with a refresh rate of 
90 Hz. The location of participants in the room was tracked using a system called 
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Lighthouse, which uses head position and the location of two handheld controllers to 
locate individuals within a rectangular space. Testing rooms were set-up with tracking 
equipment arranged at the perimeter and programmed to form a 3.5 x 3.5 metre space 
in which participants could navigate freely throughout the task. In order to improve 
comfort, minimise distractions and increase safety, a wireless backpack containing a 
laptop was used to run the task. The backpack was MSI VR One, incorporating an 
IntelR core i7 processor and weighing 3.6kg. The OLT was then controlled remotely 
by researchers through a laptop connected to the backpack via a virtual private network 
(VPN). The OLT was programmed by a UCL PhD student with a computing 
background; they made use of Unity gaming software (San Francisco, California, 
USA). 
Desktop aspects of the OLT were programmed in the Cogent 2000 Matlab 
toolbox (Wellcome Department of Neuroimaging Neuroscience: 
http://vislab.ucl.ac.uk/cogent) presented on MATLAB software on a 15 inch MacBook 
Pro, with screen resolution 1440 x 900. Responses were given via a Bluetooth 
keyboard.  
 
2.6  Magnetic Resonance Imaging (MRI) scanning 
A subsection of the aMCI group also underwent volumetric MRI scanning as 
part of their diagnostic work-up. These scans were conducted on-site at the clinical 
and research centre using 3T Siemens Prisma scanners. These scans took place within 
six months of testing and the imaging data obtained comprise the body of a joint thesis 
with Adrienne Li (2018); therefore the results of this will not be discussed further here. 
 
2.7  Object-location task (OLT) 
2.7.1  iVR component of the OLT 
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The immersive VR component of the task was made up of four active trials 
and one practice trial, with each trial divided into a ‘learning’ phase and a ‘recall’ 
phase. During the ‘learning’ phase, participants were required to first attempt to 
memorise the locations of everyday objects within a virtual world, while the 
‘recall’ phase required them to indicate where they believed each object had been 
located. The order of iVR trials is shown diagrammatically in Figure 1. Each trial 
contained three objects and was set within a different virtual environment. The 
virtual environments were enclosed by a square wall, ensuring that navigation 
relied only on distal landmark cues (see Figure 2 for examples of environments). 
Outside of this wall, a range of distal landmarks were arranged that participants 
were instructed to use to assist in locating themselves within the environment. No 
landmark cues were present within the walled portion of the environment.  
Upon entering the virtual environment for the ‘learning’ phase, participants 
were given sixty seconds to familiarise themselves with the environment, after 
which a first object was presented. Objects were presented sequentially, with only 
one object present at any time. Participants were presented with each object three 
times (i.e. 3 objects x 3 presentations), in a randomised order, and were cued to 
return to the centre of the environment between each ‘round’ of presentations. All 
objects were presented on a pedestal; in this way, it was ensured that all objects 
occupied a standardised area of the environment floor. After each object had been 
presented three times, participants were returned to a neutral grey ‘waiting room’ 
where they were given further instructions by the researcher. 
In the ‘recall’ phase, participants were given a handheld controller that 
allowed them to produce a simulated pedestal, identical to the ones on which 
objects had been placed, which they could position anywhere inside the boundary. 
The participant was then placed back into the centre of the environment and asked 
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to indicate where they believed each object had been located. Only one object 
location was presented at each time, with a small image cueing the target object 
remaining present in the corner of the screen throughout, to ensure that 
performance was not affected by difficulty in recalling the task. Participants 
indicated each choice twice, with objects again presented in a randomised order. 
The primary outcome measure from this was the displacement error of responses 
(i.e. the distance between the identified and actual object location), taken in 
centimetres; lower displacement error therefore indicated higher accuracy and 
better performance on the task.    
2.5.2  Desktop component of the OLT 
The flat screen measure of the OLT comprised two separate components: (1) 
simple object recognition; and (2) object-context recognition. Participants were, 
in the first instance, asked to identify whether an object on the screen was either 
‘old’ (i.e. had previously been seen in the iVR OLT) or ‘new’ (i.e. not presented 
in the iVR OLT). Images were presented one at a time, with each object present 
on the screen for 30 seconds. Participants were required to indicate their response 
within this time limit, or else it was recorded as an incorrect response. Where 
‘new’ objects were presented, these were foils – i.e. a different visual image of a 
concept that had been presented in the iVR OLT. For example, a foil might include 
either a previously seen ‘real’ duck, or a rubber duck that had not been previously 
presented (Figure 3 shows examples of ‘old’ objects and ‘new’ foils). 
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Lx3 
Practice 
Practice 
Active 
Active 
Active 
Active 
Active 
Active 
Active 
Active 
Rx2 
Lx3 
Rx2 
Lx3 
Rx2 
 Lx3 
 Rx2 
 Lx3 
 Rx2 
 
R = recall phase 
L = learning phase 
Figure 1: Order of presentation for VR component of the OLT 
Figure 2: Still images of the five virtual environments as seen from the perspective of 
participants. 
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  In the instance that an ‘old’ object had been presented, the participant was then 
asked to identify which environment it had been seen in; this occurred regardless 
of whether an object was correctly identified as ‘old’. Still images of all four 
potential environments were presented on the screen alongside one another, 
appearing in a random order (see Figure 4). Participants were asked to identify the 
environment that the object had been seen, again with a 30 second time limit on 
responses. An image of the target object remained on the screen alongside the 
pictures of the environment to minimise the demands of the task and to ensure that 
poor performance was due to object-environment associations, as opposed to 
difficulty recalling the object. No feedback was given on performance throughout 
these trials, however the experimental trials were preceded by a practice round, in 
which performance feedback was given. 
 
 
Figure 3: Objects used in the OLT, as presented in the desktop task. 
Original images presented on the left, foils (decoy images) presented on 
the right. 
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2.6  Neuropsychological measures 
A neuropsychological test battery comprising measures currently validated as 
a screening tool for AD and MCI were assembled. This comprised the Rey-Osterrieth 
Complex Figure Test (RCFT), as a measure of visual recognition and recall; Trail 
Making Test B (TMT-B), as a measure of executive function (Reitan & Wolfson, 
2004; Digit Symbol Test (DST; (Weschler, 1981); Free and Cued Selective Reminding 
Test (FCSRT), as an index of verbal recall under free and cued conditions (Buschke, 
1984).The Four Mountains Test (4MT) was also included in this battery as a measure 
of hippocampal-dependent spatial learning (Hartley et al., 2007). Finally, the National 
Adult Reading Test (NART) was administered as a measure of premorbid IQ (Nelson 
& Willison, 1991).  
 These measures have all been demonstrated to be sensitive diagnostic 
indicators of the early stages of AD. The FCSRT has been shown to identify the early 
stages of AD (Grober, Sanders and Lipton, 2010) and distinguish this from 
frontotemporal dementia (FTD) (Lemos, Duro and Santana, 2014). The possible 
Figure 4: Presentation of the object-context recognition condition in the 
desktop OLT. 
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outcomes from the FCSRT include both free and total recall, with the latter 
representing performance when memory was cued. In the current study we report free 
and total recall (iFR) and total recall (iTR), as well as corresponding measures for the 
delayed recall condition (dFR and dTR, respectively).  
 The RCFT is used as an index of immediate and delayed visual recall, with 
points scored based on the accuracy with which participants are able to replicate an 
image based on their recall; lower scores on this measure are therefore indicative of 
poorer performance. Visual memory indexed via the RCFT has been shown elsewhere 
to be impaired in mild AD (Kasai et al., 2006). 
 The TMT-B was used as a measure of executive functioning. The primary 
outcome measure from this is the time taken in seconds to complete the task, with 
higher scores therefore indicating poorer performance. This has been shown to have 
significant diagnostic accuracy in predicting conversion from MCI to AD, particularly 
when considered alongside EC volume and CSF biomarker status (Ewers et al., 2012). 
 The DSST requires the participant to match symbols with a corresponding 
number within a set time limit, with higher numbers representing a greater completion 
rate and, therefore, better performance. This has been shown to be a predictor of time 
to AD conversion in MCI patients (Tabert et al., 2006). 
 The 4MT task was designed as a measure of hippocampal-dependent spatial 
memory, with participants required to identify images of mountains from shifted 
viewpoints, thereby tapping allocentric spatial memory. The primary outcome from 
this is the number of correctly identified scenes, with lower scores thereby indicating 
poorer performance. As highlighted above, the 4MT has been shown to be a sensitive 
and specific predictor of conversion to AD (Moodley et al., 2015). This was carried 
out on a small, handheld computer tablet. 
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2.7  Testing procedure 
2.7.1 Structure of testing 
All testing took place on site in the Institute of Public Health (IPH) or 
the MRC Cognition and Brain Sciences Unit (CBSU), both of which belong to 
the University of Cambridge. The duration of testing was approximately 150 
minutes, although this was dependent on individual performance and could 
range between 90 and 180 minutes. Regular breaks were offered throughout to 
ensure participant comfort, as well as protecting data quality from fatigue-
related effects. Testing was carried out in three main stages: (1) an immersive 
VR task; (2) a desktop computer task, based on participation in part 1; and (3) 
a pen-and-paper neuropsychological assessment. Due to the dependence of (2) 
on participation in (1), it was necessary that these tasks were performed in that 
order. Consequently, each participant began with either the VR task or the 
neuropsychological battery in a counterbalanced manner to eliminate carry-
over effects.  
At the outset, the format of the testing session and purpose of the study 
was explained to all participants, who again were given the opportunity to read 
through the information sheet and ask any questions of the researchers. All 
participants were made aware that they could withdraw at any point. 
Subsequent to this, participants provided written informed consent for 
participation in the study (Appendix D). 
2.7.2  VR OLT procedure and instructions 
Prior to beginning the VR task, participants were fitted with a backpack 
and headset and given time to become familiar with the equipment. At this 
point, verbal instructions were again given by the researcher and a practice trial 
was initiated. Prior to beginning the VR task, participants were made aware 
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that this would be followed by a computerised task in which they were asked 
to identify the objects and environments that they encounter in the VR. During 
the ‘learning’ phase of the VR task, participants were informed of the task set 
up and structure, including the number of objects and manner of presentation. 
Once this had been completed, they were removed from the environment and 
returned to the ‘waiting room’. Participants were then given handheld 
controllers and instructed on their use, as well as allocating time to practice 
with these while still in the ‘waiting room’. Participants were returned to the 
virtual environment and began the ‘recall’ phase only when both they and the 
researcher felt that they had mastered the use of the controller.  
Researchers gave minimal further instructions after this point, except to 
indicate any transition between phases and environments. In addition, 
participants were prompted at the beginning of each trial to spend some time 
familiarising themselves with the environment and learning the landmarks in 
each new VR environment. If a participant was evidently struggling to recall 
earlier instructions or appeared to have difficulty engaging in any aspect of the 
task, the researcher would then provide additional support and instructions 
until it was felt that the participant could manage without this. 
2.7.3 Desktop OLT procedure and instructions 
After completion of the iVR component of the OLT, participants 
moved to a table-top computer. They were given task instructions verbally and 
via on screen instructions. Responses were given via a keyboard, and relevant 
keys highlighted both by visual cues and verbal instructions from the 
researcher. 
2.7.4 Neuropsychological battery 
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The neuropsychological battery was administered by a single 
researcher over one session that lasted approximately 60 minutes. Breaks were 
offered if necessary.  
 
2.8  Sample size 
A sensitivity analysis showed that for alpha = 0.05 and beta = 0.2 the study 
was powered to detect only large effects given this sample size. While this is not ideal, 
prior studies using spatial tasks had found them to be highly discriminant in similar 
samples and it was decided that the study would be valuable despite the potential to be 
somewhat underpowered. 
 
2.9 Data analysis 
All data were analysed using the Statistical Package for the Social Sciences 
(SPSS) version 25 (IBM SPSS Statistics for Windows, Version 25.0. Armonk, NY: 
IBM Corp). 
2.9.1  Group comparisons 
In order to ensure the comparability of groups, demographic information 
- namely age at testing and years of education - was compared across groups 
using independent samples t-tests. Comparisons across groups were also made 
in relation to performance on the OLT, again making use of independent samples 
t-tests; the primary OLT outcome variable was displacement error (centimetres), 
however object recognition (% accuracy) and object-environment identification 
(% accuracy) were also examined. In all instances ‘group’ (i.e. MCI or control) 
was used as the independent variable, with the relevant measures reported as a 
dependent variable. Where assumptions of normality were violated the 
appropriate non-parametric statistics were reported. Given that CSF biomarker 
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status was not available for the majority of participants, descriptive data will be 
provided that examines OLT and 4MT performance according to patient 
biomarker status. 
At this stage it is necessary to note two technical considerations in 
analysis of the data. Firstly, the initial six patients completed a version of the 
OLT including four objects per environment; this was later reduced due to 
feedback on the difficulty of the task. It was not possible to remove these 
individuals from the analysis, nor to make a statistical comparison to the 
performance of individuals who completed the three object version of the OLT 
as either analysis would be underpowered. The data were examined to determine 
the presence of any outliers or extreme scores in this group that would warrant 
removal from the analysis. Secondly, seven data points were missing from the 
conditions for object and object-environment recognition, meaning that only 
thirteen patients were included in this analysis; this was due to technical 
difficulties in data recording that affected earlier participants. It is assumed that 
this would affect the data in a non-systematic manner. 
2.9.2  Relationship to neuropsychological testing battery 
The relationship between OLT displacement error, as the primary outcome 
measure, and performance on the neuropsychological measures will be 
examined using Pearson correlations. RCFT immediate and delayed recall, 
FCSRT immediate and delayed free recall, DSST, TMT-B and the 4MT will all 
be examined in relation to their association with OLT displacement error. Raw 
scores for each outcome were used, due to the limited range of participant ages. 
Due to the high number of tests performed, Bonferroni corrections were applied. 
2.9.3  Prediction of patient status 
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Binomial logistic regression was used in order to evaluate the ability of 
each variable to correctly classify patient status (either ‘MCI’ or ‘control’) on 
the basis of OLT performance. In order to assess the independent contribution 
of variables to the prediction of patient status, variables were added sequentially 
over three stages of modelling. In the first stages, predictors of individual 
resilience, including premorbid IQ and education level (indexed by the variables 
‘NART’ and ‘Years Education’) were added to the model. This was then 
followed by 4MT as a hippocampal-dependent measure of spatial learning. 
Lastly, the variable ‘OLT displacement error’ was added as a measure of 
entorhinal-dependent spatial learning. At each stage all variables were assessed 
to determine whether they made a statistically significant contribution to 
prediction, with variables that become non-significant removed in the final 
model. The final model, including chi-square goodness of fit statistic, the 
adjusted R2 and odds ratios will be reported, alongside the contribution of each 
variable to prediction of patient status.  
A final model was constructed, again using binomial logistic regression, 
in which the ability of the comparator neuropsychological testing battery to 
correctly classify patient status (again either ‘MCI’ or ‘control’). The initial stage 
predictors of resilience factors - i.e. ‘NART’ and ‘Years Education’ – were 
added to the model at a first step, in the same way as the OLT model. At the next 
stage, the variables ‘RCFT immediate’, ‘RCFT delayed’, ‘FCSRT immediate 
free recall’, ‘FCSRT delayed free recall’, ‘TMT’ and ‘DST’ were then added to 
the model. Again, the final model statistics and independent contributions of 
each variable will be reported. This will be used as a comparator against which 
the utility of the OLT/4MT model can be assessed.  
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3        Results 
3.1  Demographics 
Overall, twenty MCI patients (males = 13) and twenty-two healthy controls 
(males = 9) took part in this study. There were no significant differences between the 
MCI and HC groups in relation to age or years of education (see Table 1 for group 
means and associated t values). Due to the high number of comparisons, Bonferroni 
corrections were applied to comparisons for the neuropsychological testing battery and 
differences assessed against a more stringent p value of .004 (.05/11). 
 
3.2 OLT performance 
Mann-Whitney U tests revealed a significantly greater error rate of object-
location displacement error for MCI patients when compared to controls (U = 85.0, p 
= .001). For the second part of the task, thirteen patients and twenty-one controls were 
included in the analysis. Where participants were not included, this was due to 
technical difficulties in data recording that prevented the analysis of this aspect of the 
OLT. There was an observable difference in object-recognition accuracy, with the 
patient group demonstrating lower accuracy than controls (U = 69.0, p = .015). 
Independent t-tests revealed no differences between MCI and control groups in terms 
of object-environment accuracy (t(32) = .779, p >.05; 95% CI = -8.24, 18.09).  
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Table 1 
 
 Demographic information and neuropsychological test performance across groups 
 
*significant difference between groups following Bonferroni correction 
 
 
 
 
 
  
 MCI (n=20)  Control (n=22)  
 Mean (SD) Mean (SD) p value 
Age 68.35 (9.65) 65.31 (7.57) .262 
Years Education  15.15 (4.09) 15.59 (3.80) .611 
ACE 85.85 (8.92) 97.91 (2.93) <.001* 
MMSE 27.6 (2.46) 29.91 (0.30) <.001* 
NART 13.4 (9.61) 5.64 (3.02) .014 
RCFT copy 32.75 (3.97) 35.96 (.21) <.001* 
RCFT immediate 13.88 (10.70) 21.66 (8.15) .011 
RCFT delayed 12.83 (11.71) 21.17 (8.15) .012 
TMT-B 145 (65.70) 70.33 (20.12) <.001* 
DST 49.50 (13.74) 66.77 (10.44) <.001* 
FCSRT iFR 21.05 (13.25) 35.55 (5.09) <.001* 
FCSRT iTR 41.15 (9.54) 47.82 (.50) <.001* 
FCSRT dFR 8.00 (6.01) 13.96 (1.46) <.001* 
FCSRT dTR 13.45 (3.97) 16.00 (.00) .001* 
Four Mountains 7.60 (3.32) 10.50 (2.04) .003* 
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Table 2 
Performance on OLT task  
 
 
 
 
 
 
 
 
3.3 Biomarker status 
Overall, four participants were identified as positive for CSF biomarkers of 
amyloid and tau. A further four individuals within the patient group were identified as 
negative according to CSF biomarkers. The remaining twelve participants were of 
unknown biomarker status. Figure 5 shows a descriptive breakdown of OLT 
displacement error and 4MT performance according to CSF biomarker status. 
 
3.4  Relationship to neuropsychological measures 
 In the case of the patient group, significant negative relationships were shown 
between OLT displacement error and performance on RCFT immediate (r(18)=-.855, 
p<.001) and delayed recall (r(17)=-.843, p<.001); FCSRT immediate (r(18)=-.882, 
p<.001) and delayed free recall (r(18)=-.893, p<.001); and DST (r(18)=-.5941, 
p=.006). No significant relationship was observed between OLT displacement error 
and performance on the NART, 4MT or the TMT-B (p>.05 in all cases). In contrast, 
for the control group there was no significant relationship observed between OLT 
displacement error and any comparator neuropsychological test (p>.05 in all cases). 
     MCI      Control 
 Mean (SD) Mean (SD) 
OLT displacement error 90.62 (53.98) 38.18 (22.28) 
Object recognition (%) 82.45 (13.31) 91.47 (6.78) 
Object-environment 
recognition (%) 
41.83 (18.41) 36.91 (17.59) 
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Figure 5: Graphs showing performance on the OLT and 4MT 
according to biomarker status 
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3.5 Prediction of patient status 
3.5.1  OLT model 
Model one The extent to which ‘NART’ score and ‘Years Education’ 
predicted patient status were added in the first stage of analysis, as these were 
characterised as resilience factors in line with ideas of cognitive reserve. A 
model containing these variables was significantly better at predicting patient 
status than a model that included only the constant (X2(1)=12.315, p<.001) and 
explained 34.6% of the variance (Nagelkerke R2). Only ‘NART’ contributed 
significantly to the predication of patient status. The variable ‘Years Education’ 
did not contribute significantly to the model (p>.05) and was therefore removed 
at this stage. Overall, this model was able to correctly predict group membership 
in 70.7% of cases. 
 
Model two At the next stage of modelling the variable ‘4MT’ score was 
added to the model to assess its independent contribution to the prediction of 
patient status. The addition of this variable significantly improved the model’s 
predictive power compared to model one (X2(2)=19.377, p<.001) and explained 
50.2% of the variance (Nagelkerke R2). This model was able to correctly predict 
group membership in 75.6% of cases, which can be further broken down to 81% 
and 70% of controls and patients respectively.  
 
Model three Finally, the contribution of the variable ‘OLT Displacement 
Error’ was added to form a last stage of the model. This stage of the model was 
significantly better at predicting patient status than model two (X2(3)=43.182, 
p<.001) and explained 86.8% of the variance (Nagelkerke R2). The classification 
accuracy of the model was improved to 95.1%, with 95.2% and 95.0% of 
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controls and patients correctly classified respectively. Coefficients, odds ratios 
and 95% confidence intervals for all variables included in the final model are 
presented in Table 3. 
 
Table 3 
Coefficients, odds ratios and associated statistics for variables included in the 
final OLT model 
 
Variable B (SE)  Significance Exp(B) (95% CI)  
NART .392  (.161) .015 1.480 (1.079, 2.030)  
4MT -.981 (.434) .024 .375 (.160, .878)  
OLT Displacement 
Error 
.092 (.039) .018 1.097 (1.016, 1.184)  
     
 
3.5.2  Comparator model 
The variables ‘RCFT immediate’, ‘RCFT delayed’, ‘FCSRT immediate 
free recall’, ‘FCSRT delayed free recall’, ‘DST’ and ‘TMT-B’ were added to a 
second binomial logistic regression, with ‘Group’ (either MCI or control) as a 
dependent measure. The first stage of modelling, in which the variables ‘NART’ 
and ‘Years education’ were added to the model were identical to the first stage 
of the OLT model; this is outlined above and therefore will not be repeated here. 
The addition of these variables significantly improved the model relative to the 
inclusion of only premorbid IQ and education level (X2(3)=39.213, p<.001) 
however only the variables ‘TMT’ and ‘FCSRT immediate free recall’ (FCSRT 
iFR) were retained for inclusion; all other variables were removed at this stage. 
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The final comparator model therefore included the variables ‘NART’, ‘TMT’ 
and ‘FCSRT immediate free recall’ and was able to account for 81% of variance 
in the data. Further, this model correctly classified 92.9% of cases; this 
constituted 100% correct identification of control and 85% of MCI cases.  
 
Table 4 
Coefficients, odds ratios and associated statistics for variables included in the final 
comparator model 
 
Variable B (SE)  Significance Exp(B) (95% CI) 
NART .147 (.138) .288 1.159 (.883, 1.520) 
TMT .050 (.025) .042 1.051 (1.002, 1.103) 
FCSRT iFR -.168 (.089) .060 .845 (0.709, 1.007) 
 
 
4 Discussion 
4.1  Main findings 
This study aimed to assess the utility of an object-location iVR task as an 
assessment tool for amnestic MCI. Here, we demonstrate that the OLT does have 
potential diagnostic use for distinguishing patients with aMCI from age-matched 
healthy controls. Patients demonstrated significantly higher rates of OLT displacement 
error relative to control participants, suggesting that this task does assess aspects of 
object-location memory that are selectively impaired in individuals with aMCI. As 
aMCI patients are a group at high risk of progression to AD, this supports the further 
investigation of the OLT as a potential early diagnostic measure. Further, this study 
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demonstrates that the OLT, when used in combination with a measure of hippocampal 
function and premorbid IQ, is able to predict patient status with a high degree of 
accuracy, correctly classifying patients in 95% of cases. In diagnostic terms, this 
represents a high degree of sensitivity to early stage deterioration in cognitive 
dysfunction associated with an aMCI diagnosis. 
This measure was designed to assess hippocampal and EC pathology, on the 
basis that these are regions known to be affected by the earliest stages of AD 
pathology. Here we see evidence that the OLT is correlated with other 
neuropsychological measures known to be sensitive to early AD, although importantly 
was not related to performance on the 4MT task, a known measure of hippocampal 
function. Not only did the two measures not correlate, but they each independently 
contributed to a predictive model of patient status. Together, this suggests that the OLT 
is sensitive to cognitive dysfunction associated with aMCI, however is distinct from 
difficulties assessed via the 4MT. It is potentially the case that in the model predicting 
patient status hippocampal dysfunction was accounted for by the 4MT, while the 
remaining variance in spatial memory due to EC dysfunction was then accounted for 
by OLT performance. However, this does not account for the lack of correlation 
between the two measures. Rather, this provides tentative support for the concept that 
the OLT taps into an earlier stage of disease progression, at which point hippocampal 
pathology may not yet be evident; i.e. the OLT may rely more heavily on object-
location memory supported by the EC. This was not an expected result based on the 
initial design of the OLT, which has some structural similarities to the hippocampal-
dependent task used in Doeller, King and Burgess (2008). One important difference 
between this and the OLT is the use of fully immersive VR that allows for free 
movement within the task, therefore incorporating self-motion information into the 
process of object-location memory in a manner that would not have been possible in 
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Doller et al. It is potentially the case that this resulted in greater reliance on the EC in 
this instance. However, in the absence of neuroimaging data this remains a speculative 
interpretation of this finding, and it is not possible to conclusively demonstrate that 
this was the case.   
Despite prior evidence that LEC lesions do not impair object recognition under 
non-associative conditions (Wilson et al., 2013), in this study we found there was 
significantly worse performance in aMCI patients relative to control participants. It is, 
however, important to note that in this instance object recognition was high across both 
groups, exceeding 80% accuracy even amongst aMCI patients. Nevertheless, the 
finding of reduced performance was not predicted in this group. These findings are 
most likely attributable to the heterogeneous nature of the participant group; only four 
individuals were confirmed as CSF positive for AD, with a further three identified as 
negative for CSF negative for amyloid and tau and the remained unconfirmed in their 
CSF status. While it would be expected that object recognition would remain 
unimpaired if pathology were limited to the EC – as is thought to be the case in the 
preclinical and prodromal stages of AD (Braak & Braak, 1991) - MCI in this instance 
is potentially (and, in some cases, certainly) due to non-AD pathology and therefore 
associated with a potentially diverse range of brain regions. It may be expected that 
were the data and sample size sufficient to allow comparisons across aetiologies, there 
may be a dissociation between those who are CSF positive and negative. However, it 
is also necessary to consider that this hypothesis is formulated from rodent data and as 
such may need further refining in order to successfully translate to human studies.  
In contrast, both MCI and control groups performed equally poorly when 
required to link objects to the environments in which they were presented and no group 
differences were observed. The poor performance is potentially related to the loss of 
data in this patient group, which may have rendered the analysis underpowered to 
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detect meaningful changes in this condition. Alternatively, it is possible that this aspect 
of the task was too complex, resulting in floor effects across groups. Indeed, it has 
been established in rodent studies that the role of the LEC and MEC in binding object 
and spatial representations may vary in line with the complexity of the task, with 
factors such as the number and diversity of objects playing a role in modulating 
performance (Save & Sargolini, 2017). Broadly, it seems that a higher number of 
objects increases cognitive demand and, consequently, requires greater LEC 
involvement (Save & Sargolini, 2017; Ku et al., 2017). This latter part of the task 
requires participants to hold in mind the object and context across all tasks, totalling 
twelve objects and four environments. While this was designed as a measure of 
recognition memory for spatial and non-spatial conjunctions, it appears that in this 
instance the cognitive load involved may be too demanding, resulting in poor 
performance across both patients and controls.  
It was not possible to comment on performance according to CSF biomarker 
status as the proportion of individuals with known biomarker status was not sufficient 
to identify any statistical differences across groups. Descriptive breakdown of the 
current results according to biomarker status showed some indication of higher OLT 
error rates in the CSF positive group relative to controls or those with CSF negative or 
unknown biomarkers. There is some variation in this, with one individual notably 
scoring among the lowest in the sample. In contrast, 4MT data did not show any clear 
differentiation according to CSF status; this is not in line with previous findings 
(Hartley et al., 2007) which have indicated a clearer breakdown in this patient group. 
This may be due to the small sample size in this study precluding the observation of 
clear distinctions according to CSF biomarker status. 
In addition to demonstrating that the OLT is a sensitive measure of cognitive 
functioning, this study aimed to assess the construct validity of this task through 
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comparators to a neuropsychological testing battery comprising the current ‘gold 
standard’ of AD assessment measures. This included measure of verbal (FCSRT) and 
visual (RCFT) immediate and delayed recall, as well as executive function (TMT-B). 
A strong negative relationship was found between performance on the OLT and 
measures of both immediate and delayed verbal and visual recall, indicating that poor 
performance on the OLT was related to poorer performance on standard 
neuropsychological measures. Further, this observation is in line with the clinical 
symptomatology of aMCI and AD as specifically associated with memory 
impairments. Interestingly, no relationship was observed between TMT and the OLT, 
which would again be clinically consistent as TMT is designed as a measure of 
executive function, a cognitive area less associated with decline in the earlier stages of 
AD. Further, the comparator model demonstrated somewhat lower accuracy in the 
prediction of patient status than did the model making use of spatial measures (i.e. the 
OLT and 4MT); this was particularly the case for the identification of the MCI group, 
with the comparator model showing lower accuracy in the identification of patients 
relative to controls (85% and 100% respectively). This is of note and tentatively 
suggests some advantages of the OLT over traditional neuropsychological measures; 
however, the difference between the predictive power of these models is small and the 
heterogeneous nature of the patient group precludes any conclusive statements in this 
regard. In order to comment on this with greater certainty it would be important to 
assess predictive power as regards the rates of transition to AD; it may be expected 
that the spatial model would show higher predictive power for those individuals who 
do go on to transition to AD. 
 
4.2  Acceptability of task 
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Given the novel nature of the task, which makes use of VR technology 
incorporating free movement tracking with visual immersion, it is helpful to briefly 
reflect on the usability of the OLT and VR environment to users with cognitive 
impairment. There were no instances in which patients failed to complete the OLT or 
withdrew consent during testing; nor, indeed were there significant outliers in which 
performance was much worse that the group mean. This, along with qualitative patient 
feedback, provides support for the acceptability of the OLT in this patient group, as 
well as the use of immersive VR technologies in this patient group. This is in line with 
previous research that supports the use of VR in MCI and AD patient groups 
(Cushman, Stein & Duffy, 2008). Given that the role of the EC is uniquely 
characterised by the integration of information from multiple sensory modalities (e.g. 
McNaughton et al., 2006), as well as the ability to integrate the spatial context of object 
recognition (Deshmukh & Knierim, 2011), this is a patient group for which immersive 
technologies may present important diagnostic potential, as the combination of 
immersive visual experiences with motion tracking software offers a unique 
opportunity to tap into the multisensory aspects of spatial cognition.  
 
4.3  Limitations 
Despite demonstrating concurrent validity, it remains to be seen whether the 
OLT will demonstrate predictive validity as regards AD. For practical reasons it was 
not possible to recruit exclusively CSF biomarker positive participants and the current 
sample therefore comprises a heterogeneous patient group. Further, the current results 
are taken at only one time point, precluding any follow-up of the conversion rate to 
AD in this sample. It is therefore not possible at this stage to comment conclusively 
on the specificity of the OLT as a diagnostic tool for MCI due to AD. In addition, the 
absence of concurrent neuroimaging data means that we cannot state with certainty 
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that the OLT in its current format specifically indexes EC functioning, rather this can 
only be inferred from knowledge regarding the neuropathology of MCI patients and 
its relation to other neuropsychological assessment tools.  
It is important to acknowledge that the control group demonstrated 
significantly higher scores on the NART, suggesting higher IQ in this group relative 
to patients. This may have arisen due to bias in the sampling, with a volunteer sample 
from a university town associated with a high likelihood of presenting with above 
average IQ; this is in contrast to a patient sample, which is drawn from a wider 
demographic area. Due to time constraints and practical limitations in the availability 
of volunteers, it was not possible at this time to recruit an alternative control group. In 
order to control for this group difference, years of education and NART error rates 
were included as a first stage in the modelling of the data; this is aimed at reducing the 
impact of this difference on any final assessment of OLT utility. However, this is only 
a partial solution to the difficulty and the sensitivity of the OLT to patient status may 
be reduced were this pre-existing difference not present (Miller and Chapman, 2001). 
It is therefore important that the current results be interpreted with caution, and future 
studies should aim to replicate these findings with a control group that is matched 
according to performance on the NART, alongside other demographic factors. 
The number of objects in each trial of the OLT was reduced during the course 
of testing, thereby introducing variation in complexity amongst patient groups; this 
represented a challenge in the current analysis. Despite piloting of the task in healthy 
samples prior to the outset of testing, issues such as this were not possible to identify 
prior to testing with a patient group precisely because they are issues specific to 
individuals with cognitive impairment; while four objects was acceptable in a non-
impaired sample, it presented a greater challenge to an MCI cohort and therefore could 
not be identified through piloting. Given the limited availability of clinical volunteers 
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and the high demands that testing places on them, it was not deemed feasible or 
appropriate to recruit this group solely for the purposes of piloting. While examination 
of the data did not identify extreme scores in those who completed the four-object 
version, it remains that this additional variation must be considered when interpreting 
the current results. 
Related to this, it is important to acknowledge that this study did not explicitly 
assess feasibility or acceptability of either the task itself or the VR set-up. While some 
information – particularly regarding drop-out rates and participant debrief discussions 
– was collected, this was on an informal basis. Adaptations to the protocol (i.e. 
changing number of objects per round) were based on this informal feedback. For this 
reason, it is not possible at this stage to make conclusive statements regarding the 
feasibility of the OLT in routine clinical practice.  In order to build on the findings of 
the current work, it would be important to carry-out a formal assessment of feasibility 
and acceptability. 
Bowen et al. (2009) set out protocols for determining the appropriateness of an 
intervention, including assessments of acceptability and any changes to protocol. The 
use of pre- and post- change surveys may be informative in determining the effect of 
changes in the OLT protocol, such as the alteration in object number described above. 
As regards acceptability to the target population, Bowen et al. propose that at the initial 
stages of design a small-scale focus group with the intended population – in this case 
MCI patients – may be carried out to more fully understand patient perceptions of the 
task. At these early stages, it would therefore be important to incorporate this form of 
feedback into future studies involving the OLT. At later stages, were the OLT to move 
towards clinical use, this may then progress to an RCT comparison of experiences of 
memory assessment via the OLT relative to assessment via routine neuropsychological 
testing. 
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A final limitation concerns that nature of the participant group – including both 
patients and controls - which was recruited from a single location within a university 
town. It is therefore likely that this groups represents a highly educated sample that 
likely does not represent a diverse sample in terms of either culture or socioeconomic 
status. This is particularly important given the known cross-cultural variations in 
performance on neuropsychological assessment tools (e.g. Ardila, 1995) as well as the 
observed cultural differences in specificity in the 4MT (Moodley et al., 2015). 
 
4.4 Further work 
The current study sought to demonstrate a proof of concept of the utility of an 
immersive VR measure of object location memory in distinguishing aMCI patients 
from non-cognitively impaired counterparts. In order to go further and demonstrate 
that the OLT is specific to EC dysfunction thought to be the hallmark of preclinical 
AD, a number of further steps must be taken. Importantly, it must be demonstrated 
that performance on the OLT is able to distinguish individuals with underlying AD 
pathology from individuals with cognitive impairment deriving from other aetiologies. 
This may be achieved in a number of ways, including the comparison of performance 
across CSF biomarker positive and biomarker negative patients. Alternatively (or, 
ideally, in parallel) a longitudinal examination of AD conversion rates over time on 
the basis of OLT performance would lend further support to the predictive utility of 
the OLT.  
Further, it is assumed that the OLT assesses abilities thought to be supported 
by EC function and, consequently, sensitive to EC dysfunction. While demonstrating 
the predictive power of OLT is an important step in supporting this conclusion, 
confirmatory neuroimaging studies would make an important contribution to this 
conclusion. It is possible that other neural regions subserving spatial memory (e.g. the 
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hippocampus) may be more heavily involved in this task. While the lack of relation to 
the 4MT in the current study suggests that this is unlikely to be the case, it would be 
important to confirm this with complimentary neuroimaging data. 
Finally, the uniformly low scores in the identification of object-environment 
conjunctions suggest that future incarnations of the OLT would benefit from reducing 
the complexity level in this part of the desktop task. This may be achieved by 
introducing a short prompt at the end of each environment encouraging participants to 
recall which objects had been recalled in that round. Alternatively, decreasing the 
similarity between environments may support participants in distinguishing between 
them when viewing a still screen image. 
 
4.5 Conclusions 
Overall, this study provides support for the use of VR technology as offering 
diagnostic potential in MCI patient groups. These results offer a proof-of concept that 
a task assessing object-location memory can successfully distinguish between aMCI 
patients and controls with a high degree of sensitivity. What is more, a model including 
measures of object-location memory and hippocampal function, when used in 
combination with premorbid functioning, was more successful than a model of pen-
and-paper neuropsychological measures in predicting patient status. These results 
would be supported by future work aligning object-location performance to 
neuroimaging data in order to assess the involvement of the EC in the current task. 
The specificity of this measure in identifying individuals at high risk of conversion to 
AD also remains to be seen and should be assessed in future research. 
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1 Overview  
This critical appraisal of the research process explores the experiential aspects 
of carrying out this study. It will begin with a consideration of the emotional aspects 
of neuropsychological assessments for individuals with cognitive impairment and how 
this may relate to their experience of testing both in traditional formats and also with 
the object-location task (OLT) specifically, and virtual reality (VR) more generally. 
Throughout, pertinent points will be illustrated by quotes from the late, great Terry 
Pratchett, being both a prominent Alzheimer’s spokesperson and one of my favourite 
authors. The second part of these reflections will concern the practical challenges that 
arose throughout the process, with a focus on the challenges associated with multisite 
collaboration and the position of visiting researcher. Finally, this appraisal will end 
with a reflection on the role of the clinician in establishing clinically-informative 
research frameworks, and how this has shaped my own sense of what is possible in 
dual clinician-researcher roles. 
  
2 Experiential aspects of testing  
The late Terry Pratchett, when reflecting on his diagnosis, wrote that 
“Alzheimer’s is me, unwinding, losing trust in myself, a butt of my own jokes and on 
bad days capable of playing hunt the slipper by myself and losing…. It steals you from 
yourself” (Pratchett, 2015) Here, there is a poignant message of the intensely personal 
nature of Alzheimer’s disease (AD) and the impact that it can have on the personhood 
of those who receive this diagnosis. Prior to beginning this research, I was allocated a 
six-month placement within a neuropsychology service, where my main role was 
providing one-off cognitive assessments, most often to individuals who had either 
suffered from strokes or were going through the process of dementia testing. Far from 
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the detached, objective process that neuropsychological screening had seemed during 
clinical teaching, I soon learned that this was one of the most highly emotive clinical 
settings that I had yet encountered. When pausing to reflect on this, it is understandable 
that this may well be the case. As Pratchett notes, one’s identity is often highly 
entwined with our own perceived abilities, as well as the memories and experiences 
that constitute our life. The public perception of dementia in general, and Alzheimer’s 
disease (AD) in particular, is that it gradually erodes not only one’s cognitive capacity, 
but the autobiographical memories of a life. It conjures images of dependence – the 
‘second childhood’ – and a reduced capacity to engage in the activities that constitute 
a meaningful engagement with life. In keeping with this concept, Steeman, Casterlé, 
Godderis and Grypdonck (2006) reviewed qualitative research into the experience of 
early stage memory difficulties and found that there was a high association with threat 
towards the sense of self-determination and meaning within society; not only this, but 
they noted an associated emotional burden of fear and uncertainty. Cognitive testing 
is unique in its ability to rapidly confront people with difficulties that they may have 
previously been unaware of having or, in some cases, may greatly fear that they are 
developing. It is little wonder then that cognitive testing is a highly emotional process 
for both examinee and examiner. What is a source of confusion, however, is a lack of 
consideration of this in relation to neuropsychological test construction. 
In the design and write-up of this study I have followed the tradition of the 
dementia literature by framing the advantages of virtual reality (VR) use in relatively 
concrete terms: the cost and usability of the software; its utility in tapping into aspects 
of neurological functioning that can’t be accessed through desktop technologies; or its 
tolerability to patients, demonstrated through task performance and drop-out rates. 
These factors are undoubtedly important when considering the use of immersive VR 
technologies in the assessment of MCI and AD, however they do not constitute the 
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whole picture. Equally important is the emotional experience of undergoing such an 
assessment. Despite this, it was not possible to include any formal assessment of the 
subjective experience of patients completing the OLT. This was primarily determined 
by the pre-existing ethical arrangements of the study, which had been set-up prior to 
our joining the research team and did not incorporate any formal assessment of the 
subjective experience of testing – e.g. a post-study follow-up questionnaire or 
qualitative interview. Nonetheless, it would have represented an important 
contribution to the research process and is an area of cognitive testing which is 
consistently overlooked.  
This reflects a consistent theme amongst the dementia literature, as well as in 
the current study, in which the medical model is undoubtedly the dominant conceptual 
framework. The use of diagnostic testing is spoken about primarily in terms of the 
validity and utility of the assessment tools, as well as the predictive power of the tools. 
These are, of course, relevant factors to consider and yet little room is given to 
discussion of the experiential process of being assessed. Here I turn again to the words 
of Pratchett, who wrote that “It occurred to me that at one point it was like I had two 
diseases – one was Alzheimer’s and the other was knowing I had Alzheimer’s. There 
were times when I thought I’d have been much happier not knowing, just accepting 
that I’d lost brain cells and one day they’d probably grow back or whatever” 
(Pratchett, 2015). This provides us with a beautiful summary of the sense that the 
assessment and diagnosis of AD itself can be so painful as to be another form of 
disease. This is in line with qualitative assessments of neuropsychological testing in 
AD populations, where it is highlighted that the process of assessment can, for many, 
feel intricately tied up in a sense of self-worth. Tolhurst (2015) carried out interviews 
with men who had dementia diagnoses to ascertain their sense of the diagnostic 
process; he found that the sense of testing could be intimately linked with a sense of 
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self, with decline in test performance associated with emotional challenges. 
Interestingly, the author notes that this difficulty wasn’t highlighted in regard to less 
detached assessment processes, such as neurological scans, suggesting that it is not the 
concept of AD or the confirmation of decline per se that presents an emotional 
challenge. Rather, the author links this to the social, relational and identity focussed 
nature of cognitive testing. It is suggested that this manner of confrontation with 
deficit, which occurs within a relationship and may be perceived to challenge the 
intellectual validity of the respondent, may be felt to more acutely undermine 
personhood than do other forms of deficit assessment (Tolhurst, 2015). 
While it was not possible to gather formal feedback on the experience of the 
OLT, it remains that myself and my fellow researchers were actively involved in all 
aspects of data collection – including both OLT and pen and paper ‘traditional’ 
neuropsychological tests. In this way, I was able to observe the impact and the 
experience that the OLT appeared to have from an observer perspective, as well as 
based on informal feedback post-testing. While it’s of course not possible to represent 
all the views given – of which there were many – it is possible to reflect on the overall 
sense of the participant experience. While it was often the case that participants found 
the pen and paper tests highly challenging, often eliciting high levels of self-criticism, 
this was reported much less frequently following completion of the OLT. While it is 
of course the case that for some individuals the OLT felt challenging and caused some 
anxiety about performance, this appeared to be far less common response than was the 
case in testing. Indeed, there were many instances in which participants reported 
finding the task enjoyable despite being aware of the challenges that it posed. This was 
reflected in the structure of the recruitment process, in which a single pool of 
participants had been invited to attend multiple VR based testing sessions, the OLT 
being the most recent of these. The fact that individuals had not only returned having 
117 
 
attended at least one previous testing session, but in many cases expressed willingness 
to return for future studies, suggests that there is something about the VR set-up that 
may feel less threatening to those who engage with it. This sense of positive emotional 
engagement with VR technology has been supported elsewhere in the literature, with 
one study finding that older adults reported a range of positive emotional experiences 
associated with the VR experience; these included references to novelty and escapism 
associated with the format, as well as a high degree of engagement and even 
excitement (Roberts, De Shuter, Franks & Radina, 2018). 
A common criticism that examinees often level at traditional 
neuropsychological assessment is the lack of relevance that it bears to their everyday 
life. Both when working as a clinician and throughout this research process I have seen 
many cases in which people respond to tests by noting that this is something that they 
would always have struggled with, and do not feel that their difficulties are represented 
by the highly abstract tasks that make up these assessments. Again, this issue was 
noted by Tolhurst (2015) in interviews with male dementia patients and their carers, 
who reported a sense that neither their aptitudes or difficulties were adequately 
represented during the process of cognitive testing, and the associated frustration that 
this could cause. This is little wonder when we consider how devoid from real life 
challenges these tests can be; when asked to connect numbers and letters, draw 
complex images from memory or count backwards in multiples of seven, it is only a 
select few who would feel that these skills comprise a significant part of their day to 
day experiences. However, the challenge has often been how to capture isolated 
cognitive functions in a manner that is both relatively specific to said function, 
standardisable and replicable, while also maintaining a sense of real-world relevance 
(or, in research terms, ecological validity). Here, perhaps VR can offer some solution. 
Pratchett wrote that “fanstasy is an exercise bicycle for the mind. It might not take you 
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anywhere, but it tones up the muscles that can.” (Pratchett & Briggs, 2013). It is not 
hard then to draw an analogy between imaginative fantasy and the ‘fantasy’ of a virtual 
world; while it may not be a direct correspondent to the real-life struggles that AD 
patients may face, perhaps it can open up a portal to the muscles that those everyday 
tasks require, as it were. In the case of the present study it would not be true to say that 
views on the task were uniformly positive, however there was no instance during 
testing when I experienced an individual reporting that the testing process did not feel 
that it measured a difficulty that felt relevant to their real-life experiences; indeed, 
misplacing objects feels perhaps one of the most common cognitive lapses for us all.  
 
3 Multisite collaboration and the role of visiting researcher 
I count myself very fortunate to have stumbled upon a project that was so 
highly set-up at the outset that a number of the challenges common to clinical research, 
such as establishing clinical links and applying for NHS ethics, were hurdles that my 
project partner and I were able to avoid. The trade-off that was made for these shortcuts 
was that all of our research was conducted off-site, in a testing centre approximately 
an hour and a half away from our home institution. In addition, the design of the 
research was in many ways constrained by the pre-existing structures already in place, 
notably the ethical approval, as well as the need to balance our demands with the 
priorities and needs of an entirely different research team. Altogether, this project was 
tied in with the research needs of both myself, my project partner and supervisor, as 
well as an additional two PhD projects and two MSc projects. This is alongside the 
overarching research aims of the senior research team, for whom volume of research 
data was a clear priority and this study was one amongst many that they were hoping 
to run within a fairly short time period. As is inevitable in such cases, each of these 
priorities was running on a different time scale and therefore decisions as to how and 
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when many aspects of the research would be carried out did not run to a time-scale 
that was ideal for myself and my partner. In addition, I had to make peace with a lower 
level of control over the research process than I would typically be comfortable with. 
Here, I would like to take the time to reflect on a one such issue that we encountered, 
and the learning I’ve taken from them. 
One of the key challenges that arose was in the time scale and specifics of 
recruitment, which was handled largely by a research nurse affiliated with the off-site 
research team. The designation of an individual specifically to support with 
recruitment was a massive asset to this study, and their hard work undoubtedly saved 
myself and my project partner a great deal of time in calling and administration. An 
additional factor in the decision to have recruitment handled on-site was that our 
visiting researcher status granted us access to buildings, data and testing facilities, 
however did not grant computer access. This greatly restricted the involvement that 
we were able to have in the screening of participants, given that patient data was held 
securely on an on-site server. Due to pressures to recruit in an accelerated time-frame 
and a lack of access to patient data, there was an initial lack of clarity as regards the 
nature of the participants that we were recruiting. While it was always agreed that our 
research would focus on an MCI patient cohort, it was initially thought that this may 
focus specifically on those individuals who had also tested as positive for 
cerebrospinal fluid (CSF) biomarkers of b-amyloid and neurofibrillary tau, giving our 
data greater specificity to an AD diagnosis. During initial discussions with senior 
research investigators it had been thought that this would have been a possibility due 
to the high number of potential patients from which we could recruit. However, when 
we then broached this issue with those responsible for recruitment it emerged that this 
was not possible nor had this been a factor in those patients who were recruited for the 
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study. While this did not in essence change the rationale or execution of the study, it 
did underline for me how easy it was for miscommunications to occur that had the 
potential to alter our research in a significant way. This difficulty was resolved, with 
communication between, myself, my project partner and our supervisor, as well as 
through discussions that took place.  
From this incident, I have taken a number of points. Firstly, I found that large 
research teams come with a number of advantages, but also their fair share of 
challenges. While there are undoubted benefits in terms of the broader range of 
thinking and potential to divide the work load, to name but a few, communication 
amongst team members becomes far more complex. On one level, there were 
communication challenges involved in co-ordinating a complex research set-up, 
involving multiple sites and a large amount of technical equipment, with my fellow 
researchers with whom I had no day-to-day contact. This was also evident in our 
assumptions that the information that had been given to us regarding patient 
recruitment had also been conveyed to all members of the off-site research team. Given 
the large number of people and locations involved, it became difficult to arrange that 
all team members were in the same place at the same time, and this led to issues of 
miscommunication where such assumptions were made. At another level, there are 
often differing priorities and aims between more senior researchers and staff, such as 
myself, working at the ground level. While for myself and my colleagues the aim was 
more clearly invested in the practical running of this individual study, it is necessary 
for more senior colleagues to focus on broader aims, with this study being only one 
amongst many that are being planned. Therefore practical details, such as was the issue 
with participant recruitment, can at times become lost through miscommunication. On 
reflection, I do feel that this was an issue that was noted at an early stage and significant 
efforts were made to increase regular effective communication. However, in the future 
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I would have this in mind before engaging in any multi-site research project and ensure 
that from the outset a clear method for consistent communication across all team 
members is in place, with clear structures for including colleagues at all levels of the 
research project.  
Secondly, I found that I as a researcher can find it a challenge to feel in some 
ways out of control within the research process. At every stage of this study my own 
research was dependent on the support of multiple colleagues; this was true in terms 
of the design of the computer and VR tasks, the technical set-up of the equipment and 
the recruitment of participants. Further, all data were stored on-site at the testing 
location, meaning that I did not have access to hard copies of the data in between 
testing session. In all of my previous research experience, I have taken on the role of 
research assistant; in this role, I have had a high level of control over the hard copies 
of the data and have worked primarily within single-site projects and a close research 
team (both in terms of professional relationships and physical proximity). This was 
therefore a new experience for me and one that required some adjusting. I found this 
a particular challenge during the process of write-up, where acquiring many aspects of 
the data – e.g. demographic information, data collected outside of the testing session 
– would require my requesting this from a PhD student on-site at the testing centre, 
who had access to both hard copies of data and the computer databases that I was 
unable to reference. Of course, they were incredibly helpful and responsive, which 
meant that no major difficulties came up in this regard. However, I did realise within 
myself that this lack of control feels very uncomfortable, and my desire to check and 
verify various aspects of data collection had to be restrained more so than is usually 
the case. This was an important opportunity for me to sit with the discomfort of feeling 
that control was shared amongst a number of team members; through this I have come 
to understand the importance of sharing equal responsibility and of relinquishing a 
122 
 
need to feel so highly involved in every aspect of the research process. Further, this 
encouraged me during the process of write-up to shift my focus from the smaller 
details of project management to the broader sense of the narrative and over-arching 
aims of the project; for example, rather than attempting to re-check and re-analyse the 
data multiple times in order to understand an unexpected result, I instead took a step 
back and thought about how this might make sense in the context of our particular 
patient group, and what alternative theoretical perspective might say about this issue. 
In this way, I feel that I have learned the personal and academic benefits of sharing 
involvement in research in a meaningful way, and have attempted to take a step back 
from a need to control or manage all aspects of a project. 
 
4 The clinical research process 
A final brief space here must go to my observations of the recruitment set-up 
that allowed this research to take place. As is highlighted in the methods section of my 
empirical paper, our patient sample was recruited directly through their attendance at 
the memory clinic, with all participants initially approached via their attending 
clinician. As part of the pre-recruitment and testing stage of research myself and my 
project partner sat in on several clinic sessions, as the senior researcher in our guest 
institution was also, in most cases, the clinician who gave the MCI diagnoses and 
approached individuals about research. Here I was impressed at the dedication that this 
clinician showed both to the clinical aspects of their role, but their ability to think about 
the broader potential to use this dual-position for the increasing research opportunities. 
Of course, there are difficulties with this manner of recruitment, primary among which 
is the fact that the process of diagnosis is a very sensitive one, and that individuals can 
feel grateful to and obligated to comply with the wishes of their clinician when asked 
if they are willing to participate in research, or may not have had time to consider the 
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request in greater detail. This then raises some questions about whether individuals are 
truly comfortable with consenting to taking part in research. However, what we did 
find throughout recruitment was that those individuals who did not, after reflection, 
wish to take part did feel able to give this feedback when subsequently approached by 
the research team and therefore did fairly quickly appear to withdraw from the 
research.  
What was evident was that many of the barriers often encountered in carrying 
out clinically relevant research, such as finding and establishing relationships with 
disconnected clinical teams, did not feel to be an issue in this instance. Rather, there 
was an impressive amount of joined-up thinking about the clinical and research reality 
of the individuals in the study; this was evident both in small, practical ways, such as 
the ease of access to diagnostic information, but also in the broader process issues such 
as the familiarity of conversations between participants and the research team. Further, 
because of the close links between the research team, participants and clinical team, 
there was a clear consideration of each participants personal situation when planning 
the testing session. This felt particularly salient for me as an individual on the cusp of 
qualification, considering not only how I would like to place myself as regards the 
clinical settings that I work within, but also how I would want to balance this with 
potential future work in research. This encouraged me to think that there is an 
important and vital role for clinicians in actively participating in and establishing 
frameworks for the routine carrying out of clinically-relevant research. 
 
5 Conclusions 
The issues considered here highlight the clinical and practical learning that can 
be taken from even highly technical or neuroscience-focussed theses. Despite the 
veneer of objectivity and detachment that can surround neuropsychological 
124 
 
assessment, there is undoubtedly a high degree of emotional content involved in both 
the process and the outcome of diagnosis. This appraisal considered how this was 
relevant in the context of the current research, as well as how this may apply more 
broadly to technological advances in AD assessment. It also put forward personal 
learning for myself in terms of the benefits and challenges of multisite collaboration 
within research, how this might intersect with my own experiences and preferences as 
a researcher, and the ways in which I might take this forward in the future. I also reflect 
on the ways in which the research process has informed my views on the importance 
of dual clinician and researcher roles, and the unique position that they offer in terms 
of increasing research opportunities and promoting clinical thinking within research 
teams. Finally, I would like to end with a concluding quote from Terry Pratchett, which 
aptly summarises the process of learning through difficulties and mistakes:  
“That was always the dream, wasn't it? 'I wish I'd known then what I know now'? But 
when you got older you found out that you NOW wasn't YOU then. You then was a 
twerp. You then was what you had to be to start out on the rocky road of becoming you 
now, and one of the rocky patches on that road was being a twerp.”  (Pratchett, 2002). 
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Department of Clinical Neurosciences  
Dr Dennis Chan PhD MD FRCP 
 
PARTICIPANT INFORMATION SHEET 
 
Study title: VIrtual Reality Testing of Entorhinal Cortex and Hippocampal 
function in Alzheimer’s Disease (VIRTECH-AD) 
IRAS ID: 193437 
 
 
Part 1 - Background:  
We would like to invite you to take part in a research study that uses virtual 
reality/augmented reality (VR/AR) technology to test spatial navigation (getting from 
A to B) and spatial memory (remembering the location of objects) in people with 
mild cognitive impairment 
You have been asked to participate in this research because your memory clinic 
specialists have diagnosed you with mild cognitive impairment. 
Before you decide to take part we would like you to understand why the research is 
being done and what it would involve for you. Please take time to read the following 
information carefully. You can talk to others about the study if you wish or ask one of 
the researchers for further information. 
What is the purpose of the study? 
Spatial navigation and memory are abilities controlled by regions of the brain called 
the entorhinal cortex and the hippocampus, which are the first brain regions to be 
affected by Alzheimer’s disease (AD). As such, when people are in the earliest stages 
of AD, these abilities will be impaired and if we can identify this impairment will help 
detect AD in its very earliest stages. At present, when people such as yourself are 
Herchel Smith Building for Brain and Mind 
Sciences 
Forvie Site, Robinson Way 
                          Cambridge CB2 0SZ  
Tel: 0044 (0)1223 760697 
Fax: 0044 (0)1223 336 581 
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diagnosed with mild cognitive impairment on clinical grounds, it is not possible to know 
whether this may be due to AD unless specialised and invasive tests (amyloid-PET 
brain scanning or lumbar puncture studies) are undertaken. It would therefore be 
greatly desirable to have new tests that in the future can help doctors understand 
whether a person’s mild cognitive impairment is due to AD. 
The problem is that it is not practical to test people’s spatial navigation and memory 
in real world settings such as parks or streets. However, current wearable VR/AR 
technology provides a solution to this problem. VR headsets (see Figure 1, left) give 
the wearer the experience of being immersed within a virtual environment (Figure 1, 
right), within which they can move around using hand-held controls. By comparison, 
AR headsets generate artificial objects and scenes (holographic images) 
superimposed on the real world (hence the term “augmented reality”). While this does 
not have the advantage of VR in creating a fully immersive simulated environment, 
the ability to perceive the real world as well as the simulated images may prove less 
disorientating. 
Together, these novel technologies provide previously unavailable opportunities to 
test spatial navigation and memory in a way that may be applied in clinical practice. 
 
Figure 1. Left: a wearable VR headset. Right: an example of the immersive virtual 
environment visualised by the headset wearer. 
 
However, to date, VR/AR has not been used for testing spatial navigation or memory 
in people with early AD. To do so, we need to undertake studies to investigate which 
VR/AR technology can be used to help diagnose early AD and also  to obtain 
feedback on whether people experience any problems with these tests, such as 
nausea or a sense of disorientation while moving around within the simulated 
environment using the VR/AR headsets. Any such feedback will be used to adjust the 
test in order to prevent these issues in the future.  
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Do I have to take part? 
Participation in this study is entirely voluntary. We will describe this study to you and 
go through this information sheet, which will be given to you. Should you decide to 
take part, we will ask you to sign a consent form. You are free to withdraw from the 
study at any time, with no need to give a reason.  
 
What does participating involve? 
This study requires you to wear a VR or AR headset. At the beginning of the study 
you will be invited to use a VR headset (the HTC Vive, currently available 
commercially). As the study proceeds, the study team will have access to an AR 
headset (the Microsoft Hololens, not yet available commercially) and you will be 
asked if you would like also to be tested using this headset. 
It takes less than ten minutes to get used to the headsets. You will be asked to 
explore a simulated scene which a number of everyday objects (such as a vase or a 
ball) are placed at specific locations. Once you have familiarised yourself with this 
scene and with the VR or AR  equipment, you will be tested on your ability to 
navigate within the simulated scene and your memory for the location of these 
everyday objects.  
You will be tested once with the VR headset and once with the AR headset, if you 
agree to return at a later date for testing with the latter. Each test will take around 30 
minutes. 
At the end of the testing period we will ask you a few questions about your 
experience during the task, and in particular whether you experienced any 
discomfort or disorientation during the task.  
 
Who will have access to my medical records? 
Your medical records will be reviewed by the study team before you start the study 
to check your eligibility for the study. 
In addition to the study team, your records may be reviewed as part of an auditing 
process carried out by the R & D department. These audits serve to uphold rules 
relating to good clinical practice. 
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What happens to the study data? 
Research data will be stored for 10 years. All personal identifiable data will be 
stored on NHS computers held in lockable offices and password-protected. These 
data will be held for 10 years before being destroyed. 
 
Will I be told about the results from this study? 
Yes. We will endeavour to inform you of the results of tests. Furthermore our aim is 
to present the study results at public-patient meetings and you will be invited to attend 
these meetings. These presentations will describe the overall study results rather than 
results on individuals and will not refer to you, or any other participant, personally or 
in any other way that would compromise your anonymity. 
In the event that my condition deteriorates and my mental capacity is lost, what 
will happen to my personal data? 
Assuming that you gave your consent at the beginning of the study, the research 
team would retain the study data collected and continue to use it confidentially in 
connection with the purposes for which consent is being sought. 
Expenses and Payments 
We will be able to contribute £20 to the cost of travel to our research site. 
What are the possible disadvantages and risks of taking part? 
There are no major disadvantages or risks associated with participation. However, 
some users may find VR headsets makes them feel sick and/or disorientated. It is 
important that if you experience any of these problems that you make the researcher 
aware so they can stop the test.  
What are the possible benefits of taking part? 
There are no immediate benefits to you. However, if the study is successful in its aims, 
then it will help us diagnose AD in its very earliest stages. 
 
What if there is a problem? 
131 
 
If you have a concern about any aspect of the study or wish to make a complaint, 
you can speak to one of the researchers who will do their best to answer your 
questions or address your complaint, or by contacting Dr Dennis Chan in writing, or 
by telephone 01223 760696.  If you wish to express concerns or complaints to 
someone outside the research team then you are advised to contact the Patient 
Advisory and Liaison Service (PALS), Addenbrooke’s Hospital, Cambridge. 
 
Confidentiality – who will have access to the data? 
If you join this study your personal information and the data we collect will be stored 
on a secure network and only the research team will have access to it. Since we 
work with other researchers worldwide in the study of AD, it is possible that these 
researchers may analyse anonymised data arising from this study, abiding by the 
terms of formal collaborations between the University of Cambridge and other 
academic institutions. In such instances your personal details will not be shared. 
 
What will happen to the results of the research study? 
The results of the study will be published in scientific journals. Participant data will be 
anonymised so that it is not possible for you to be identified in published articles.  
Who is organising and funding the research? 
This study is organised by Dr Dennis Chan and funded by the Medical Research 
Council and by Alzheimer’s Research UK. The study results will be analysed by Dr 
Chan’s research group.  
 
Contact details 
If you have any queries, please contact Dr Dennis Chan in writing, or by telephone 
01223 760696. 
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Appendix E 
Statement regarding joint thesis contributions 
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Testing was carried out jointly by Elizabeth Harding (EH) and project partner, 
Adrienne Li (AL; DClinPsy student, UCL). Other researchers who contributed to the 
testing of patients were David Howitt (DH; PhD student, University of Cambridge), 
Emma Barham (EB; Research Nurse, University of Cambridge), Zoe Adler (ZA; 
MSc student, University of Cambridge) and Volker Reisner (VR; MSc student, 
University of Cambridge).  
AL’s DClinPsy thesis also makes use of OLT data, however the focus is on the 
relation to neuroimaging MRI measures. 
EH and AL carried out virtual reality testing for all of the aMCI patient group and 
approximately half of control participants.  
Neuropsychological testing was carried out by EH, AL, EB and ZA, with EB and ZA 
carrying out the majority of testing. 
Scoring and analysis of neuropsychological testing data was carried out solely by 
EH. 
Scheduling of participants was carried out by EB and DH. 
Lumbar punctures, from which CSF data was gathered, was carried out by EB. 
MRI scanning of the aMCI patient group was scheduled by DH, and analysed by AL, 
DH, ZA and VR. 
 
